alpha-aminopyridine has been researched along with Breast Neoplasms in 367 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (0.27) | 29.6817 |
| 2010's | 165 (44.96) | 24.3611 |
| 2020's | 201 (54.77) | 2.80 |
| Authors | Studies |
|---|---|
| Babbar, N; Bardia, A; Campos-Gomez, S; Chow, L; Colleoni, M; Franke, F; Harbeck, N; Hurvitz, S; Im, SA; Jung, KH; Lee, KS; Lu, YS; Rodriguez Lorenc, K; Sohn, J; Solovieff, N; Su, F; Taran, T; Tripathy, D; Vázquez, RV | 1 |
| Carayannopoulos, L; Cheng, Y; Li, Y; Reyes, J; Tong, Z; Wang, X; Zhou, S | 1 |
| Barsky, AR; Clark, A; Dastgheyb, S; Dreyfuss, AD; Freedman, GM; Kim, KN; Shah, P; Taunk, NK | 1 |
| Andersson, M; André, V; Barriga, S; Cortés, J; Del Mastro, L; Fasching, PA; Forrester, T; Goetz, MP; Guarneri, V; Hamilton, E; Harbeck, N; Hegg, R; Huang, CS; Jaliffe, GG; Johnston, SRD; Kreipe, H; Martin, M; Munoz, M; Nabinger, SC; O'Shaughnessy, J; Rastogi, P; Rugo, HS; San Antonio, B; Senkus, E; Shahir, A; Shao, ZM; Sherwood, S; Sohn, J; Steger, GG; Tamura, K; Testa, L; Toi, M; Tolaney, SM; Tryakin, A; Wei, R | 1 |
| Araki, K; Hamada, M; Ikeda, T; Minamoto, K | 1 |
| Goetz, MP; Kawaguchi, T; Mori, J; Takahashi, M; Tanizawa, Y; Toi, M; Tokunaga, E; van der Walt, JS | 1 |
| Cheng, MY; Gao, HF; Ji, F; Li, JQ; Niu, G; Wang, K; Yang, CQ; Yang, M; Zhang, JS; Zhang, LL; Zhang, QZ; Zhu, T | 1 |
| Alberti, M; Basile, D; Buzzo, M; Canil, G; Gagno, S; Gerratana, L; Guardascione, M; Iacuzzi, V; Montico, M; Orleni, M; Pelizzari, G; Poetto, AS; Posocco, B; Puglisi, F; Toffoli, G; Zanchetta, M | 1 |
| Lagampan, C; Parinyanitikul, N; Poovorawan, N | 1 |
| Harbeck, N; Johnston, S; O'Shaughnessy, J; Rastogi, P; Shahir, A | 1 |
| Anand, K; Düster, R; Geyer, M; Gray, NS; Kaltheuner, IH; Moecking, J; Wang, J | 1 |
| Bardia, A; Foukakis, T; Matikas, A; Spring, L | 1 |
| Freedman, RA; Giordano, SH; Somerfield, MR | 1 |
| Chen, Y; Kawaguchi, T; Masuda, N; Ohno, S; Saji, S | 1 |
| Burstein, HJ; Curigliano, G; Hamilton, EP; Hurvitz, SA; Krop, IE; Lin, NU; Rugo, HS; Schnitt, SJ; Tarantino, P; Tolaney, SM; Winer, EP | 1 |
| Brucker, S; Busse, A; Decker, T; Fasching, P; Fehm, T; Gjerga, E; Grunert, C; Hennig, S; Janni, W; Keilholz, L; Keller, U; Kümmel, S; Lüftner, D; Na, IK; Peuker, CA; Schaper, S; Schneeweiss, A; Schuler, M; Yaghobramzi, S | 1 |
| Babu, KG; Bardia, A; Campos-Gomez, S; Cardoso, F; Chakravartty, A; Chow, L; Colleoni, M; De Laurentiis, M; El-Saghir, N; Franke, F; Gasch, C; Harbeck, N; Hurvitz, S; Im, SA; Im, YH; Ji, Y; Jung, KH; Kuemmel, S; Lee, KS; Lu, YS; O'Regan, R; Sohn, J; Solovieff, N; Tripathy, D; Villanueva Vazquez, R; Wang, C; Wang, Y; Wheatley-Price, P | 1 |
| Banala, VT; Gautam, S; Gupta, A; Marwaha, D; Mishra, PR; Mitra, K; Mittapelly, N; Rai, N; Sharma, M; Singh, N; Urandur, S | 1 |
| Asghar, US; Kanani, R; Mittnacht, S; Roylance, R | 1 |
| Beck, JT; Chan, A; Chandiwana, D; De Laurentiis, M; Delea, TE; Fasching, PA; Im, SA; Jerusalem, G; Lanoue, B; Lonshteyn, A; Martin, M; Neven, P; Nusch, A | 1 |
| Amiri-Kordestani, L; Beaver, JA; Bloomquist, E; Ghosh, S; Kalavar, S; Mixter, BD; Mulkey, F; Osgood, C; Pazdur, R; Philip, R; Pierce, WF; Rizvi, F; Roy, A; Royce, M; Tang, S | 1 |
| Kinoshita, T; Sakurada, A; Sakurai, T; Seki, H; Shimizu, K | 1 |
| Grischke, EM; Jansen, VM; Litchfield, LM; Llombart-Cussac, A; Neven, P; Sledge, GW; Sohn, J; Soliman, H; Toi, M; Tolaney, SM; Wang, H; Wijayawardana, S | 1 |
| Abdel-Razeq, H; Cardoso, F; Cottu, P; De Laurentiis, M; Marchetti, P; Martín, M; Menon-Singh, L; Ring, A; Salvador Bofill, J; Wu, J | 1 |
| Ali, J; Baboota, S; Biswas, L; Sahoo, PK; Sartaj, A; Verma, AK | 1 |
| Abdel-Rahman, O; de Sousa, MJ; Fazio, N; Gervaso, L; Meneses-Medina, MI; Spada, F | 1 |
| André, F; Arteaga, CL; Burris, HA; Cameron, DA; Campone, M; Chakravartty, A; Conte, P; Hart, L; Hortobagyi, GN; Janni, W; Le Gac, F; O'Shaughnessy, J; Petrakova, K; Serra, P; Sonke, GS; Stemmer, SM; Taran, T; Winer, EP; Yap, YS; Zarate, JP | 1 |
| Denaro, V; Francesco, P; Iuliani, M; Longo, UG; Napolitano, A; Orsaria, P; Ribelli, G; Santini, D; Simonetti, S; Tonini, G; Vincenzi, B | 1 |
| Fleming, GF; Francis, PA; Pagani, O; Regan, MM; Walley, BA | 1 |
| Lavenia, G; Martorana, F; Prestifilippo, A; Ricciardi, GR; Rossello, R; Sanò, MV; Sava, S; Vigneri, P | 1 |
| Blancas, I; Boyle, F; Broom, R; Brown, J; Campone, M; Gumus, M; Hulstijn, M; Im, YH; Johnston, SRD; O'Shaughnessy, J; Rastogi, P; Reinisch, M; Rugo, HS; San Antonio, B; Shahir, A; Song, C; Toi, M; Tolaney, SM; Wei, R; Yamashita, T; Zagouri, F; Zimmermann, A | 1 |
| Jacobson, A | 1 |
| Freedman, RA; Giordano, SH; Graff, SL; Somerfield, MR; Telli, ML; Wolff, AC | 1 |
| Curigliano, G; Jin, Q; King, TA; Mittendorf, EA; Tarantino, P; Tolaney, SM | 1 |
| Çelik, H; Çil, T; Duman, BB; Erçolak, V; Eser, K; İnal, A; Kesen, O; Köşeci, T; Önder, AH; Öztürk, B; Sezer, E | 1 |
| Ando, H; Ebi, H; Fukushima, S; Hashimoto, N; Irie, K; Iwata, H; Maeda, A; Matsuzaki, M; Morishige, JI; Okada, A; Sawaki, M | 1 |
| Dixit, J; Gupta, D; Gupta, N; Gupta, S; Jyani, G; Kalaiyarasi, JP; Kataki, A; Krishnamurthy, MN; Kumar, L; Malhotra, P; Malik, PS; Mathew, A; Mehra, N; Prinja, S; Rajsekhar, K; Roy, PS; Singh, A | 1 |
| Cuyun Carter, G; Gathirua-Mwangi, WG; Huang, YJ; Morato Guimaraes, C; Nash Smyth, E; Price, GL; Rajkumar, J; Ryan, P; Rybowski, S; Sheffield, KM; Sudharshan, L | 1 |
| Ateş, Ö; Karaçin, C; Özdoğan, S; Şeyran, E; Türkel, A; Yekedüz, E | 1 |
| Beniak, J; Borstnar, S; Gal-Yam, EN; Kudela, P; Palacova, M; Papazisis, K; Rubovszky, G; Timcheva, C; Łacko, A | 1 |
| Higashi, T; Mase, K; Mizutani, M; Moriya, T; Ozawa, K; Takagi, S; Takei, S; Takeshita, A; Yokoyama, M | 1 |
| Adamchuk, H; Dakhil, S; Denduluri, N; Fernandez, MM; Forrester, T; Garcia-Saenz, JA; Grecea, D; Headley, D; Hegg, R; Johnston, SRD; Kim, SB; Lacko, A; Martin, M; Okera, M; Oksuzoglu, B; Ouyang, Q; Papazisis, K; Reeves, J; Schenker, M; Shimizu, C; Testa, L; Wei, R; Zimmermann, A | 1 |
| Cushman, J; Hamilton, E; Moore, H; Sammons, S | 1 |
| Aske, J; De, P; Dey, N; Koirala, N | 1 |
| Al-Samkari, H; Shatzel, JJ; Wander, SA; Watson, NW | 1 |
| Baquero, C; Bian, H; de Dios, A; Du, J; Ganado, MP; Lallena, MJ; Marugan, C; Mur, C; Puig, O; Torres-Guzmán, R; Yang, Y; Zeng, Y | 1 |
| Chen, SC; Chen, Y; Cortes, J; Hamilton, E; Hegg, R; Huober, J; Jerusalem, G; Manikhas, A; Martin, M; Ozyilkan, O; Petrakova, K; Zhang, W | 1 |
| Boyle, F; Chapman, SC; Chen, Y; Ezquerra, MB; Gable, JC; Gainford, MC; Goksu, SS; Hossain, AM; Lim, E; Loi, S; Okera, M; Price, GL; van Hal, G | 1 |
| Chao, TC; Huang, CC; Lai, JI; Lin, CY; Liu, CY; Tseng, LM; Yu, CJ | 1 |
| Goel, S; Litchfield, LM; Morato Guimaraes, C; O'Brien, N; O'Dea, D; Slamon, DJ; Wander, SA | 1 |
| Arumí, M; Ciruelos, E; Falato, C; Ferrer, N; Gavilá, J; Gil-Gil, M; Gómez, G; González-Santiago, S; Hernando, C; Izarzugaza, Y; Montaño, A; Muñoz, M; Najera-Zuloaga, J; Paré, L; Pascual, T; Prat, A; Saura, C; Villacampa, G; Villagrasa, P | 1 |
| Agrawal, KU; Barke, MR; Shields, CL | 1 |
| Abbinante, G; Arcara, C; Bisagni, G; Coltelli, L; Faggioni, G; Geuna, E; Grasso, D; Gunnellini, M; Livi, L; Moretti, G; Ragni, F; Rinaldi, G; Sanna, G; Scotti, V; Staropoli, N; Vannini, L; Verderame, F | 1 |
| Haddad, N; Huang, CS; Im, YH; Sakaguchi, S; Sledge, GW; Sohn, J; Toi, M; van Hal, G; Zhang, W | 1 |
| Johnston, SRD; Martin, M; Wei, RJ | 1 |
| Sun, R; Wei, LJ | 1 |
| Asano, Y; Kashiwagi, S; Morisaki, T; Nakamura, Y; Nakatsukasa, H; Noda, S; Takahashi, K; Takahashi, M; Takashima, T | 1 |
| Atake, Y; Bun, A; Fujimoto, Y; Fukui, R; Hattori, A; Higuchi, T; Imamura, M; Kanaoka, H; Miyoshi, Y; Murase, K; Nagahashi, M; Natori, K; Ozawa, H; Takatsuka, Y | 1 |
| Alvarez Lopez, IM; Anton Torres, A; Barnadas Molins, A; Bellet Ezquerra, M; Cantos Sanchez de Ibargüen, B; Ciruelos Gil, EM; de Casa, S; De la Cruz Merino, L; De la Haba-Rodriguez, J; de Toro Salas, R; Delgado Mingorance, JI; Diaz Fernandez, N; Galve Calvo, E; Gavila Gregori, J; Gimeno, A; Gonzalez-Santiago, S; Hernando Melia, C; Jiménez-Rodriguez, B; Martin, M; Martínez Jañez, N; Moreno Anton, F; Quiroga Garcia, V; Rodriguez Sanchez, CA; Salvador Bofill, J; Vicente Rubio, E; Vidal, M; Villanueva Vazquez, R | 1 |
| Acar, Ö; Aksoy, S; Aykan, MB; Çelebi, A; Chalabiyev, E; Doğan, A; Dursun, B; Erdoğan, AP; Günenç, D; Güven, DC; Hacıbekiroğlu, İ; İnanç, M; Kahraman, S; Kaman, Ö; Keskinkılıç, M; Kılıçkap, S; Melisa Celayir, Ö; Mutlu, E; Ön, S; Özen, M; Vedat Bayoğlu, İ; Yalçın, Ş; Yavuzşen, T; Yıldırım, HÇ | 1 |
| Angelini, L; Bargagna, I; Biondani, P; Crucitta, S; D'Onofrio, R; Danesi, R; De Giorgi, U; Del Re, M; Fogli, S; Fontana, A; Giontella, E; Livi, L; Lorenzini, G; Meattini, I; Mongillo, M; Natalizio, S; Omarini, C; Palleschi, M; Porta, C; Stucci, S | 1 |
| Boyle, F; Grimes, BR; Im, YH; Jiang, Z; Johnston, SRD; Molthrop, D; Nabinger, SC; Reinisch, M; Sapunar, F; Toi, M; Wei, R | 1 |
| Baba, K; Funasaka, C; Harano, K; Hosono, A; Kawamoto, M; Kawasaki, T; Kondoh, C; Kusuhara, S; Mamishin, K; Matsubara, N; Mukohara, T; Naito, Y; Nakajima, H; Nakao, T; Sasaki, T | 1 |
| Arpino, G; Barchiesi, G; De Laurentiis, M; Del Mastro, L; Di Lauro, V; Fontanella, C; Giuliano, M; Martorana, F; Muratore, M; Puglisi, F; Zucchini, G | 1 |
| Araz, M; Artaç, M; Çağlayan, D; Eryılmaz, MK; Geredeli, Ç; Göksu, SS; Koçak, MZ; Tatlı, AM | 1 |
| Ge, R; Jiang, ZF; Wang, BY | 1 |
| Habler, K; Kalla, AS; Rychlik, M; Teupser, D; Vogeser, M | 1 |
| Al-Samkari, H; Shatzel, JJ; Watson, NW | 1 |
| Araz, M; Artaç, M; Er, MM; Eryılmaz, MK; Hendem, E | 1 |
| Chakraborty, A; Ji, Y; Miller, M; Quinlan, M; Serra, P; Wang, Y; Yartsev, V | 1 |
| Blair, HA; Fung, S | 1 |
| Caruso, M; Gebbia, V; Giotta, F; Martorana, F; Piazza, D; Sanò, MV; Spada, M; Valerio, MR; Vigneri, P | 1 |
| Iwata, H; Nozawa, K; Sawaki, M | 1 |
| André, V; Johnston, SRD | 1 |
| Ahmadu, C; Armstrong, N; Coughlan, D; Duffy, S; Kernohan, A; Kleijnen, J; McDermott, K; O'Meara, S; Orozco Leal, G; Robinson, T; Vale, L | 1 |
| Coutinho, A; Cui, ZL; Karuturi, M; Lokhandwala, T; Lunacsek, O; Ring, A; Rybowski, S; Sapunar, F; Sheffield, KM; Smyth, EN; Willey, J | 1 |
| Allegrini, G; Arpino, G; Benelli, M; Bianchi, GV; Bianchini, G; Caputo, R; Castelletti, D; Cazzaniga, ME; Colleoni, M; De Laurentiis, M; Del Mastro, L; Di Marino, M; Guarneri, V; Malorni, L; Montemurro, F; Orditura, M; Paris, I; Puglisi, F; Tamberi, S; Zamagni, C; Zambelli, A | 1 |
| Bruno, S; Fancellu, A; Fedele, P; Giuliani, F; Guarini, C; Iaia, ML; Laface, C; Maselli, FM; Melaccio, A; Perrone, M; Sanna, V; Santoro, AN | 1 |
| Amiri-Kordestani, L; Bloomquist, E; Mulkey, F; Osgood, C; Royce, M | 1 |
| Gebbia, V; Martorana, F; Sanò, MV; Valerio, MR; Vigneri, P | 1 |
| Harbeck, N; Johnston, SRD; Martin, M; O'Shaughnessy, J; Rastogi, P; Tolaney, SM | 1 |
| Goldstein, DA; Gyawali, B; Meirson, T; Tannock, IF | 1 |
| Fakhouri, W; Faris, LH; Haro, JM; Kawaguchi, T; Novick, D; Nozawa, K; Onishi, M; Ozaki, Y; Takano, T; Tanizawa, Y; Terada, M; Tsurutani, J | 1 |
| Aguiar-Bujanda, D; Álvarez, I; Andrés, R; Antón, A; Bermejo, B; Carrasco, E; Chacón, JI; Cruz, J; Guerrero, Á; Jara, C; Lopez-Tarruella, S; Martín, M; Martínez, P; Miralles, JJ; Muñoz, M; Polonio, Ó; Ramos, M; Rodríguez-Lescure, Á; Ruiz-Borrego, M; Santaballa, A; Servitja, S | 1 |
| Bouganim, N; Brezden-Masley, C; Edwards, S; Gelmon, K; Henning, JW; Hilton, JF; Jerzak, KJ; Sehdev, S | 1 |
| Barrios, C; Cameron, D; Emde, A; Gnant, M; Janni, W; Johnston, S; Martin, M; Neven, P; Srock, S | 1 |
| Hashishita, H; Kuwahara, S; Maeda, H; Takada, S; Takahashi, M; Tomioka, N; Umehara, K; Watanabe, K; Yamamoto, M | 1 |
| Clarke, R; Goetz, MP; O'Sullivan, CC; Robertson, J | 1 |
| de Leng, WWJ; de Vos, FYFL; de Wit, GF; Espinoza, D; Gelderblom, H; Geurts, BS; Hoes, LR; Jansen, AML; Lee, CK; Leek, LVM; Lin, FP; Looze, EJ; Roepman, P; Sebastian, L; Simes, RJ; Sjoquist, KM; Thavaneswaran, S; Thomas, DM; van Berge Henegouwen, JM; van der Noort, V; van der Wijngaart, H; van Herpen, CML; Verheul, HMW; Voest, EE; Zeverijn, LJ | 1 |
| Chakraborty, A; Chakravartty, A; Darstein, C; Ho, YY; Ji, Y; Quinlan, M; Yang, S; Zarate, JP | 1 |
| Aruga, T; Babbar, N; Balbin, OA; Chiu, J; Ishikawa, T; Joshi, M; Masuda, N; Su, F; Yap, YS; Zarate, JP | 1 |
| Hayashi, M; Hirata, A; Kimura, K; Morita, S; Takashima, Y; Terasawa, R | 1 |
| André, F; Arteaga, CL; Babbar, N; Bardia, A; Chia, S; Hortobagyi, G; Lteif, A; Lu, YS; Neven, P; Slamon, D; Solovieff, N; Su, F; Taran, T; Tripathy, D | 1 |
| Bauer, S; Decker, T; Denkert, C; Filmann, N; Hirmas, N; Loibl, S; Lorenz, R; Lübbe, K; Lüdtke-Heckenkamp, K; Melnichuk, L; Müller, V; Mundhenke, C; Schmidt, M; Seropian, P; Thill, M; Zahm, DM; Zahn, MO | 1 |
| Aogi, K; Futamura, M; Hosonaga, M; Imamura, CK; Iwasa, T; Iwata, H; Kawabata, H; Masuda, J; Masuda, N; Matsumoto, K; Miura, S; Mukohara, T; Sakai, H; Takahashi, M; Takano, T; Tanabe, Y; Tomioka, N; Tsurutani, J; Yamochi, T; Yasojima, H; Yoshimura, K | 1 |
| Chang, CM; Lam, HYP | 1 |
| Ahmed, KA; Arrington, JA; Etame, AB; Figura, NB; Forsyth, PA; Han, HS; Liu, JK; Mohammadi, H; Oliver, DE; Potluri, TK; Robinson, TJ; Sahebjam, S; Soliman, H; Tran, ND; Yu, HM | 1 |
| Han, X; Lu, C; Lv, S; Qiao, P; Ren, C; Sun, Y; Wang, D; Wang, L; Yang, T; Yu, Z | 1 |
| Johnston, SR; Lee, KA; Shepherd, ST | 1 |
| de Dios, A; Lallena, MJ; Sánchez-Martínez, C; Sanfeliciano, SG | 1 |
| Ay, B; Bozkaya, Y | 1 |
| Arpino, G; Bachelot, T; Cristofanilli, M; De Laurentiis, M; De Placido, P; De Placido, S; Del Mastro, L; Generali, D; Giordano, A; Giuliano, M; Jerusalem, G; Milani, M; Pistilli, B; Prat, A; Puglisi, F; Rognoni, C; Schettini, F; Thomas, G; Venturini, S | 1 |
| Grellety, T; Meynard, L | 1 |
| Buchanan, S; Enatsu, S; Hayashi, S; Maeda, K; Sakaguchi, S; Sato, A; Tamaki, C | 1 |
| Barriga, S; Burdaeva, O; Conte, P; Frenzel, M; Grischke, EM; Hurt, K; Inoue, K; Johnston, S; Kaufman, PA; Koh, H; Llombart-Cussac, A; Lu, Y; Masuda, N; Neven, P; Okera, M; Pivot, X; Sledge, GW; Sohn, J; Toi, M | 1 |
| Stirrups, R | 1 |
| Killock, D | 1 |
| Aoun, M; Assi, T; Awada, A; Farhat, F; Kanj, A; Kattan, J; Tarabaih, M | 1 |
| Melegari, E; Palleschi, M; Rocca, A | 1 |
| Im, SA; Lu, YS; Tripathy, D | 1 |
| Tamura, K | 1 |
| Lu, H; Luo, Q; Wang, Y; Zhou, X | 1 |
| Kiely, BE; Mok, K; Moylan, E; Nguyen, R; Wilson, BE | 1 |
| Beck, JT; Bianchi, GV; Chakravartty, A; Chia, S; De la Cruz-Merino, L; De Laurentiis, M; Esteva, FJ; Fasching, PA; Im, SA; Jerusalem, G; Martín, M; Neven, P; Nusch, A; Petrakova, K; Pivot, X; Rodriguez-Lorenc, K; Slamon, DJ; Sondhi, M; Sonke, GS; Taran, T; Wang, Y | 1 |
| Cristofanilli, M | 1 |
| El Zein, N; Hachem, R; Hilal, G; Raad, I; Sarkis, R; Tahtouh, R; Wardi, L | 1 |
| Bentham, RB; Bianchi, K; Carter, E; Dalli, J; Godinho, SA; Grose, R; Hodivala-Dilke, K; Holdsworth, J; Ironside, A; Jones, L; Jones, W; Mataloni, I; Moreno Béjar, R; Szabadkai, G; Uhlik, L; Wilcz-Villega, E; Xu, R | 1 |
| Dunst, J; Fabian, A; Krug, D | 1 |
| Bascialla, L; De Giorgi, A; Gallerani, E; Giaquinto, A; Grigioni, E; Gueli, R; Marrazzo, C; Nigro, O; Pinotti, G; Vallini, I | 1 |
| Andre, V; Carter, GC; Grischke, EM; Kaufman, PA; Neven, P; Price, GL; Shekarriz, S; Sledge, GW; Sohn, J; Stoffregen, C; Toi, M | 1 |
| André, T; Bay, JO; Bouleuc, C; Hervé, L; Magné, N; Penel, N; Rodrigues, M; Sabatier, R; Thiery-Vuillemin, A; Wislez, M | 1 |
| Buisseret, L; de Azambuja, E; Eiger, D; Nogueira, MS; Pondé, NF; Wagner, M | 1 |
| Figlia, G; Kaya, O; Martin-Villalba, A; Romero-Pozuelo, J; Teleman, AA | 1 |
| André, F; Catron, K; Chan, A; Chapman, SC; Gainford, MC; Goel, S; Hilton, JF; Im, SA; Johnston, SR; Kim, SB; Price, GL; Ricci, F; Tolaney, SM; Troso-Sandoval, TA; Wardley, AM; Yang, Z; Zambelli, S | 1 |
| Battisti, NML; Ring, A | 1 |
| Ball, S; Sultan, A; Swarup, S; Thein, KZ | 1 |
| O'Shaughnessy, J | 1 |
| Beitsch, P; Patel, R; Whitworth, P | 1 |
| Briceño-Casado, MDP; Fénix-Caballero, S; Gil-Sierra, MD | 1 |
| Kim, DH; Sun, R; Wei, LJ | 1 |
| Frenzel, M; Sledge, GW | 1 |
| Hindié, E | 1 |
| Jerusalem, G; Slamon, DJ | 1 |
| Barbolini, M; Dominici, M; Molinaro, E; Omarini, C; Piacentini, F | 1 |
| Andre, V; Gainford, MC; Goetz, MP; Huober, J; Johnston, S; Martin, M; Park, IH; Price, GL; Shekarriz, S; Stoffregen, C; Toi, M; Tokunaga, E | 1 |
| Firenze, A; Gebbia, V; Valerio, MR; Vigneri, P | 1 |
| Aruga, T; Chiu, J; Gazdoiu, M; Gounaris, I; Han, Y; Ishikawa, T; Ito, Y; Ji, Y; Kim, SJ; Masuda, N; Saeki, T; Saito, M; Su, F; Toyama, T; Yap, YS | 1 |
| Aquilano, M; Cerbai, C; Desideri, I; Dominici, L; Livi, L; Marinko, T; Meattini, I; Orazem, M; Ratosa, I; Ribnikar, D; Scoccimarro, E; Steinacher, M | 1 |
| Chigutsa, E; Kambhampati, SRP; Karen Sykes, A; Posada, MM; Turner, PK; van der Walt, JS | 1 |
| Anders, CK; Awada, A; Bachelot, T; Bear, M; Chan, A; Chapman, SC; Chen, Y; Conte, P; Diéras, V; Kabos, P; Le Rhun, E; Lin, NU; Sahebjam, S; Tolaney, SM; Yang, Z; Yardley, D | 1 |
| Abdelhady, AM; Ji, Y; Rodriguez Lorenc, K; Samant, TS; Yang, S | 1 |
| Guarino, S; Massaioli, C; Stocchi, L | 1 |
| Chang, YC; Chao, TY; Chen, SC; Chitapanarux, I; Gao, M; Jung, KH; Kim, JH; Lee, KS; Liu, CT; Lu, YS; Park, YH; Shotelersuk, K; Slader, C; Sohn, J; Tseng, LM; Valenti, R; Yang, Y | 1 |
| Ameye, L; Awada, A; Azambuja, E; Brandão, M; Caparica, R; De Angelis, C; Desmedt, C; Di Cosimo, S; Eiger, D; Franzoi, MA; Kotecki, N; Lambertini, M; Piccart, M; Ponde, N | 1 |
| Atienza, M; Cassinello, A; Ciruelos, E; Garcia-Saenz, JA; Llombart, A; Manso, L; Martin, M; Ringeisen, F | 1 |
| Feng, X; Han, H; Sun, T; Xu, J; Zhou, W | 1 |
| Alongi, F; Buglione, M; Costantino, G; Figlia, V; Guerini, AE; Maddalo, M; Magrini, SM; Pasinetti, N; Pedersini, R; Pedretti, S; Pegurri, L; Peretto, G; Salah, E; Simoncini, EL; Triggiani, L; Vassalli, L | 1 |
| Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y | 1 |
| Chang, A; Cheng, D; Huang, S; Liu, AT; Sun, P; Tan, X; Wang, G; Wang, J; Wang, Q; Wu, D; Xiang, R; Yang, S; Zhao, S | 1 |
| Ando, H; Ebi, H; Fukushima, S; Hashimoto, N; Irie, K; Iwata, H; Kajita, M; Maeda, A; Okada, A; Sawaki, M | 1 |
| Kishino, E; Koike, Y; Kurebayashi, J; Ogata, R; Saitoh, W | 1 |
| Amir, E; Desnoyers, A; Kumar, V; Nadler, MB; Saleh, R | 1 |
| Abdelhady, AM; Bachelot, T; Calvo, E; Fasolo, A; Forero-Torres, A; Hamilton, E; Im, YH; Lee, SC; Lu, YS; Maur, M; Nardi, L; Ruan, S; Stammberger, U; Tiedt, R; Tolaney, SM | 1 |
| Wolff, AC | 1 |
| Boyle, F; Campone, M; Cicin, I; Cortés, J; Cox, J; Frenzel, M; Guarneri, V; Hamilton, E; Harbeck, N; Headley, D; Hegg, R; Hulstijn, M; Huober, J; Johnston, SRD; Martin, M; Martinez Rodriguez, JL; Neven, P; O'Shaughnessy, J; Okada, M; Rastogi, P; San Antonio, B; Shao, ZM; Smith, IC; Sohn, J; Toi, M; Tolaney, SM; Wardley, A; Wei, R; Zhang, QY | 1 |
| Andre, VAM; Barriga, S; Cox, J; García-Sáenz, JA; Goetz, M; Huober, J; Masuda, N; Rugo, HS; Sohn, JH | 1 |
| Beijnen, JH; Groenland, SL; Huitema, ADR; Martínez-Chávez, A; Schinkel, AH; Steeghs, N; van Dongen, MGJ | 1 |
| Awada, A; El Hachem, G; Gombos, A | 1 |
| Beck, JT; Bianchi, GV; Chan, A; Chandiwana, D; De Laurentiis, M; Esteva, FJ; Fasching, PA; Jerusalem, G; Lanoue, B; Martin, M; Neven, P; Nusch, A; Pivot, X; Ridolfi, A; Rodriguez Lorenc, K; Wang, Y | 1 |
| Jerusalem, G; Neven, P; Sonke, GS | 1 |
| Aziz, MIA; Lee, SC; Loke, L; Ng, K; Pearce, F | 1 |
| de Luna, A; Fuentes-Antrás, J; García-Sáenz, JÁ; López de Sá, A; Moreno, F; Ocaña, A | 1 |
| Alexandre, J; Chretien, B; Da Silva, A; Emile, G | 1 |
| Clark, AS; DeMichele, A; Makhlin, I | 1 |
| Bear, MM; Chapman, SC; Chen, SC; Cortes, J; Hamilton, E; Hardebeck, MC; Hegg, R; Huober, J; Jerusalem, G; Johnston, EL; Lu, Y; Manikhas, A; Martin, M; Ozyilkan, O; Petrakova, K | 1 |
| Díaz Almirón, M; García-Trevijano Cabetas, M; Herrero Ambrosio, A; Jiménez Nácher, I; Lucena Martínez, P; Zamora Auñón, P | 1 |
| Alhudaithi, SS; Almuqbil, RM; Bielski, ER; Bos, PD; da Rocha, SRP; Du, W; Sunbul, FS; Zhang, H | 1 |
| Asai, S; Hirashima, T; Hozaka, Y; Kijima, Y; Nohata, N; Ohtsuka, T; Okada, R; Seki, N; Shinden, Y; Tanaka, T; Toda, H | 1 |
| Curigliano, G | 1 |
| Alfonso, F; Alvarado-Casas, T; Rivero, F; Salamanca, J; Vera, A | 1 |
| Björnsson, ES; Finnsdottir, S; Sverrisdottir, A | 1 |
| Canova, C; Klausner, G; Troussier, I | 1 |
| Harbeck, N | 1 |
| Cardoso, F; Di Cosimo, S; Porcu, L | 1 |
| Jian, L; Lian, S; Liu, M; Liu, N; Wang, S; Zhang, G; Zhang, Y; Zhao, Q | 1 |
| Ait-Oudhia, S; Franco, YL; Mody, H; Perez, L; Ramakrishnan, V; Vaidya, TR | 1 |
| André, VAM; Campone, M; Chouaki, N; Goetz, MP; Grischke, EM; Manso, L; Okera, M; San Antonio, B; Sledge, GW; Toi, M; Wildiers, H | 1 |
| Printz, C | 1 |
| Asou, H; Chen, Y; Mori, S; Noma, S; Sakaguchi, S; Taguchi, Y; Takahashi, M; Tomii, K; Tsurutani, J | 1 |
| Akiyama, Y; Doi, S; Hagihara, K; Matsushita, K; Motoki, Y; Nakaguchi, K; Sakisaka, H | 1 |
| Ji, Y; Miller, M; Samant, TS; Yang, S | 1 |
| Bananis, E; Cameron, C; Haltner, A; Hooper, B; Mitra, D; Rugo, HS; Tran, A; Zhan, L | 1 |
| Agostinetto, E; de Azambuja, E; Debien, V; Lambertini, M; Marta, GN; Piccart-Gebhart, M | 1 |
| Huang, P; Huang, X; Lin, S; Rao, X; Wang, H; Weng, X; Zeng, D | 1 |
| André, VAM; Chen, SC; Enatsu, S; Goetz, MP; Hae Park, I; Hardebeck, MC; Im, SA; Inoue, K; Iwata, H; Masuda, N; Sakaguchi, S; Sledge, GW; Sohn, J; Toi, M; Turner, PK | 1 |
| Ho, YY; Ji, Y; Lu, Y; Yang, S | 1 |
| Berg, T; Jensen, AB; Kodahl, AR; Kristensen, KB; Thomsen, IMN | 1 |
| Erdal, GS; Gulturk, I; Ozmen, A; Tacar, SY; Tural, D; Yilmaz, M | 1 |
| Abuhelwa, AY; Badaoui, S; Hopkins, AM; McKinnon, RA; Modi, ND; Rowland, A; Shankaran, K; Shaw, E; Sorich, MJ | 1 |
| Badaoui, S; Hopkins, AM; Kichenadasse, G; Rowland, A; Sorich, MJ | 1 |
| Doerler, M; Gambichler, T; Ocker, L; Stranzenbach, R; Susok, L | 1 |
| Balakrishna, S; Bowman, L; Cohen, AB; Cuyun Carter, G; Gossai, A; Huang, YJ; Mathur, R; Morato Guimaraes, C; Nash Smyth, E; Rasmussen, E; Rybowski, S; Seidman, AD; Sheffield, KM; Zhu, YE | 1 |
| Kudo, S; Makino, T; Tanaka, T; Umetsu, R | 1 |
| Gallagher, P; Haynes, HR; Mohan, V; Mozayani, B | 1 |
| Chandiwana, D; Delea, TE; Park, J; Stellato, D; Thabane, ME | 2 |
| Abe, M; Chiba, R; Ishiguro, A; Ito, K; Kato, H; Kubota, R; Matsunami, O; Narita, Y; Ohigashi, A; Tanimoto, A | 1 |
| Jung, US; Kim, DH; Kim, HS; Kim, MG; Min, KW | 1 |
| Beck, JT; Chakravartty, A; Chia, S; De la Cruz-Merino, L; De Laurentiis, M; Deore, U; Fasching, PA; Im, S; Jerusalem, G; Ji, Y; Martín, M; Neven, P; Nusch, A; Petrakova, K; Slamon, DJ; Sonke, GS; Taran, T; Valeria Bianchi, G; Wang, C; Zarate, JP | 1 |
| Cottu, P; Coussy, F; Deluche, E; Ferrero, JM; Ladoire, S; Pistilli, B | 1 |
| Bardia, A; Burris, HA; Chan, A; Chia, S; Esteva, FJ; Hart, L; Im, SA; Lorenc, KR; Neven, P; Ridolfi, A; Sohn, J; Thaddeus Beck, J; Tripathy, D; Yardley, DA; Zarate, JP | 1 |
| Adamo, B; Bellet, M; Brasó-Maristany, F; Carey, LA; Chic, N; Ciruelos, E; Cortés, J; Galván, P; Gavilá, J; González-Farré, B; Martínez, D; Martínez-Sáez, O; Muñoz, M; Oliveira, M; Pascual, T; Pernas, S; Perou, CM; Prat, A; Sanfeliu, E; Saura, C; Schettini, F; Soberino, J; Vidal, M | 1 |
| Besiroglu, M; Gucin, Z; Seker, M; Shbair, AT; Simsek, M; Sucuoglu, Z; Topcu, A; Turk, HM; Yasin, AI; Yurtsever, I | 1 |
| Akamatsu, H; Arteaga, CL; Brewer, MR; Brown, BP; Chatterjee, S; Hanker, AB; He, J; Jayanthan, HS; Koch, JP; Lalani, AS; Lee, KM; Lin, CC; Marín, A; Meiler, J; Servetto, A; Sheehan, JH; Sudhan, DR; Ye, D | 1 |
| Bajpai, J; Elamarthi, P; Ghosh, J; Gulia, S; Gupta, S; Kembhavi, Y; Mokal, S; Nandhana, R; Parab, P; Perumal, P; Rath, S | 1 |
| Abbas, H; Lim, Z; Malik, AA; Oo, ZM | 1 |
| Burdaeva, O; Conte, P; Grischke, EM; Haddad, N; Hurt, KC; Inoue, K; Johnston, SRD; Kaufman, PA; Koh, H; Llombart-Cussac, A; Lu, Y; Masuda, N; Neven, P; Okera, M; Pivot, X; Sledge, GW; Sohn, J; Toi, M | 1 |
| Azim, HA; Bofill, JS; Borstnar, S; Campone, M; Chatterjee, S; Ciruelos, E; Cottu, P; De Laurentiis, M; Dent, S; Jacot, W; Lu, J; Martin, M; Menon-Singh, L; Ring, A; Warner, E; Wu, J; Zamagni, C; Zhou, K | 1 |
| Goetz, MP; Haddad, N; Hurt, KC; Iwata, H; Kaufman, PA; Lu, Y; Neven, P; Rugo, HS; Sledge, GW; Toi, M; Tolaney, SM | 1 |
| Balbin, A; Cresta, S; Crystal, A; Curigliano, G; De Vita, S; Duhoux, FP; He, W; Huober, J; Jhaveri, K; Ji, Y; Juric, D; Kundamal, N; Layman, RM; Sheng, Q; Takahashi, S; Terret, C; Yap, YS | 1 |
| Mullard, A | 1 |
| Blackwell, KL; Sammons, SL; Topping, DL | 1 |
| Criscitiello, C; Curigliano, G; Esposito, A; Intra, M; Minucci, S | 1 |
| Syed, YY | 1 |
| Liu, Q; Mani, S; Pestell, RG; Wu, K; Xu, H; Yu, S; Yuan, X | 1 |
| Peplow, M | 1 |
| Arteaga, CL; Awada, A; Baselga, J; Campone, M; Chia, S; Clemons, M; Cortés, J; De Laurentiis, M; Dharan, B; Di Tomaso, E; Hachemi, S; Hurvitz, S; Im, SA; Ito, Y; Iwata, H; Jagiełło-Gruszfeld, A; Jiang, Z; Jonat, W; Massacesi, C; Masuda, N; Pistilli, B; Takahashi, M; Tseng, LM; Urban, P; Vuylsteke, P | 1 |
| Griggs, JJ; Wolff, AC | 1 |
| Barriga, S; Bourayou, N; Burdaeva, O; Frenzel, M; Grischke, EM; Inoue, K; Kaufman, PA; Koh, H; Lin, Y; Llombart-Cussac, A; Masuda, N; Neven, P; Okera, M; Pivot, X; Sledge, GW; Smith, IC; Sohn, J; Toi, M | 1 |
| Carneiro, BA; Costa, R; Costa, RB; Giles, FJ; Gradishar, WJ; Helenowski, I; Kaplan, J; Peterson, J; Talamantes, SM | 1 |
| Fan, Y; Guo, Q; Huang, Z; Li, Y; Liu, Y; Wang, T; Wang, X; Xiang, R; Xu, G; Yang, S; Zhang, C | 1 |
| Akıncı, MB; Bilgin, B; Sendur, MAN; Şener Dede, D; Yalçın, B | 1 |
| Chen, S; Huang, TT; Liu, CY; Petrossian, K; Tseng, LM; Wu, CY | 1 |
| Bardia, A; Moy, B; Spring, LM; Zangardi, ML | 1 |
| Kwapisz, D | 2 |
| Echavarria, I; Jerez, Y; López-Tarruella, S; Márquez-Rodas, I; Martin, M | 1 |
| Dees, EC; Henderson, GE; Reeder-Hayes, KE; Roberts, MC | 1 |
| Caponigro, G; Germa, C; Hewes, B; Hirawat, S; Miller, M; Mukhopadhyay, P; Scherer, SJ | 1 |
| Criscitiello, C; Curigliano, G; Viale, G | 1 |
| Bardia, A; Blouin, GC; Spring, LM; Zangardi, ML | 1 |
| Baselga, J; Bermejo, B; de la Pena, L; Denkert, C; Gombos, A; Kümmel, S; Lee, SC; Loi, S; Loibl, S; Lux, M; Michiels, S; Nekljudova, V; Piccart, MJ; Rezai, M; Steger, G; Turri, S; Untch, M; Urban, P; Von Minckwitz, G; Zardavas, D | 1 |
| Autret, A; Bertucci, F; Boher, JM; Camerlo, J; Campone, M; Charafe-Jauffret, E; Extra, JM; Gonçalves, A; Guerin, M; Hervieu, A; Isambert, N; Lokiec, F; Pakradouni, J; Provansal, M; Rezai, K; Sabatier, R; Viens, P | 1 |
| Messina, C; Messina, M; Zanardi, E | 1 |
| Barriga, S; Bourayou, N; Campone, M; Chen, SC; Di Leo, A; Forrester, T; Freedman, OC; Frenzel, M; Garnica Jaliffe, G; Goetz, MP; Huober, J; Manso, L; Paluch-Shimon, S; Park, IH; Smith, IC; Sohn, J; Toi, M; Trédan, O | 1 |
| Pondé, N; Tryfonidis, K; Zardavas, D | 1 |
| Alba, E; Bachelot, T; Burris, HA; Campone, M; Erdkamp, F; Favret, AM; Germa, C; Hart, LL; Hegg, R; Jakobsen, E; Janni, W; Miller, M; Sonke, GS; Souami, F; Sutradhar, S; Verma, S; Villanueva, C; Wheatley-Price, P; Wist, E | 1 |
| Kim, ES | 1 |
| Iacobucci, G | 1 |
| Anders, CK; Carey, LA; Dees, EC; Hu, Z; Kornblum, ZA; Marcom, PK; McRee, AJ; Moore, DT; Perou, CM; Phipps, R; Reeder-Hayes, K; Weck, KE; Zamboni, WC | 1 |
| Arteaga, CL; Beck, JT; Cameron, DA; Conte, P; Germa, C; Hart, LL; Hortobagyi, GN; Jakobsen, E; Lindquist, D; Mondal, S; O'Shaughnessy, J; Petrakova, K; Sonke, GS; Souami, F; Villanueva, C | 1 |
| Augereau, P; Berton Rigaud, D; Bourbouloux, E; Campone, M; Frenel, JS; Gourmelon, C; Patsouris, A; Robert, M | 2 |
| Bachelot, T; Chan, S; Farci, D; Han, HS; Jerusalem, G; Kong, A; Massacesi, C; Mouhaër, SL; Pistilli, B; Pluard, T; Robinson, D; Saura, C; Tomaso, ED; Urban, P; Urruticoechea, A | 1 |
| Aghaei, M; Jafari, SM; Joshaghani, HR; Panjehpour, M | 1 |
| Bachelot, T; Blau, S; Bordonaro, R; Ciruelos, E; Csőszi, T; Decker, T; Dharan, B; Di Leo, A; Egle, D; El-Hashimy, M; Janni, W; Johnston, S; Kalev, D; Lee, KS; Lønning, PE; Mouret-Reynier, MA; O'Regan, R; Schirone, A; Sellami, D; Tjan-Heijnen, VCG; Weber, D | 1 |
| Andre, F; Bailleux, C; Bardia, A; Condorelli, R; Dubois, J; Iafrate, AJ; Lacroix, L; Lanman, RB; Nagy, RJ; O'Shaughnessy, J; Scott, V; Spring, L | 1 |
| Belli, C; Criscitiello, C; Curigliano, G; D'Amico, P; Duso, BA; Locatelli, M; Mazzarella, L; Minchella, I; Trapani, D; Viale, G | 1 |
| Iwata, H | 1 |
| Alba, E; Auñón, PZ; Bachelot, T; Beck, TJ; Campone, M; Diab, S; Esteva, FJ; Gil-Gil, M; Janni, W; Kral, Z; Lopez, R; Miller, M; Pluard, TJ; Richards, P; Ryvo, L; Sutradhar, S; Tsai, M; Ward, P | 1 |
| Alebachew, E; Beaver, JA; Bi, Y; Bloomquist, E; Blumenthal, GM; Chang, CJG; Fu, W; Goldberg, KB; Ibrahim, A; Liu, Q; Palmby, TR; Patel, P; Pazdur, R; Pierce, WF; Shah, A; Sridhara, R; Tang, S; Tilley, A; Yu, J; Zhao, P | 1 |
| Burris, HA | 1 |
| Hernández-Steller, H; Landaverde, DU; Ramos-Esquivel, A; Savard, MF | 1 |
| Corona, SP; Generali, D | 1 |
| Kotake, T; Toi, M | 1 |
| Assi, T; Bakouny, Z; El Rassy, E; Kattan, J | 1 |
| Alba, E; Burris, HA; Campone, M; Chandiwana, D; Dalal, AA; Janni, W; Monaco, M; O'Shaughnessy, J; Sutradhar, S; Verma, S | 1 |
| Bardia, A; Spring, L | 1 |
| Arteaga, CL; Blackwell, KL; Burris, HA; Cameron, DA; Campone, M; Conte, P; Elmeliegy, M; Germa, C; Hortobagyi, GN; Janni, W; Miller, M; Mondal, S; O'Shaughnessy, J; Paluch-Shimon, S; Petrakova, K; Sonke, GS; Stemmer, SM; Su, F; Verma, S; Winer, EP; Yap, YS | 1 |
| Dhar, V; Parylo, S; Patibandla, P; Sokoloff, A; Vennepureddy, A | 1 |
| Gonçalves, A | 1 |
| Abdel-Razeq, H | 1 |
| Bhattacharyya, D; Bhattacharyya, S; Biskupiak, J; Brixner, D; Dalal, AA; May, JR; Mishra, D; Mistry, R; Oderda, G; Suri, G; Tang, D; Young, K | 1 |
| Babu, KG; Bardia, A; Campos-Gomez, S; Carlson, G; Chow, L; Colleoni, M; De Laurentiis, M; Diaz-Padilla, I; El-Saghir, N; Franke, F; Germa, C; Harbeck, N; Hirawat, S; Hughes, G; Hurvitz, SA; Im, SA; Im, YH; Jung, KH; Kuemmel, S; Lee, KS; Liu, MC; Lu, YS; Sohn, J; Tripathy, D; Villanueva Vazquez, R; Wheatley-Price, P | 1 |
| Foukakis, T | 1 |
| Beck, JT; Bianchi, GV; Chia, S; De la Cruz-Merino, L; De Laurentiis, M; Esteva, FJ; Fasching, PA; Im, SA; Jerusalem, G; Martín, M; Miller, M; Neven, P; Nusch, A; Petrakova, K; Pivot, X; Rodriguez Lorenc, K; Slamon, DJ; Sonke, GS; Taran, T; Vidam, G; Wang, Y | 1 |
| Romero, D | 1 |
| Lynce, F; Shajahan-Haq, AN; Swain, SM | 1 |
| Abraham, J; Lee, SS; Scott, SC | 1 |
| Fojo, T; Laderian, B | 1 |
| Bjelic-Radisic, V; Kapp, KS; Partl, R; Pötscher, M; Regitnig, P; Tauber, G | 1 |
| Bhattacharyya, D; Bhattacharyya, S; Biskupiak, J; Brixner, D; Dalal, AA; Hettle, R; May, JR; Mishra, D; Mistry, R; Oderda, G; Suri, G; Tang, D; Young, K | 1 |
| Hecht, KA; Selby, C | 1 |
| Lau, G; Palumbo, A; Saraceni, M | 1 |
| Desideri, I; Livi, L; Meattini, I; Scotti, V; Simontacchi, G | 1 |
| Augereau, P; Bourbouloux, E; Campone, M; Frenel, JS; Gourmelon, C; Patsouris, A; Rigaud, DB; Robert, M | 1 |
| Al, MJ; Armstrong, N; Büyükkaramikli, NC; de Groot, S; Duffy, S; Fayter, D; Kleijnen, J; Portegijs, P; Riemsma, R | 1 |
| Arteaga, CL; Awada, A; Baselga, J; Bourdeau, L; Campone, M; Chia, S; Clemons, M; Cortés, J; De Laurentiis, M; El-Hashimy, M; Hurvitz, S; Im, SA; Ito, Y; Iwata, H; Jagiełło-Gruszfeld, A; Jiang, Z; Jonat, W; Le Mouhaër, S; Masuda, N; Pistilli, B; Sankaran, B; Sellami, D; Tseng, LM | 1 |
| Aplin, AE; Teh, JLF | 1 |
| Afghahi, A; Diamond, JR; Shagisultanova, E; Weiss, J | 1 |
| Ma, J; Peng, L; Tan, C; Wan, X; Zeng, X; Zhang, Y | 1 |
| Balkenhol, M; Beißbarth, T; Blazquez, R; Bleckmann, A; Evert, M; Hanisch, UK; Korf, U; Perera-Bel, J; Proescholdt, M; Pukrop, T; Reinz, E; Riemenschneider, MJ; Ritter, U; Salinas, G; Schatlo, B; Schildhaus, HU; Schulz, M; Seitz, S; Siam, L; Stadelmann, C; Utpatel, K; Vollmer, E; Wachter, A; Wiemann, S; Wlochowitz, D; Wolff, A | 1 |
| Cardoso, F; Ribnikar, D; Volovat, SR | 1 |
| Choo, JR; Lee, SC | 1 |
| Bøttcher, TM; Cold, S; Jensen, AB | 1 |
| Bacon, J; Bonventre, JV; Chappell, JC; Chiang, AY; Hall, SD; Kulanthaivel, P; Pak, YA; Royalty, J; Turner, PK | 1 |
| Finn, RS; Friedlander, M; Lee, CK; Lee, KWC; Lim, E; Loi, S; Lord, S; Lynch, J; Martin, A | 1 |
| Niraula, S | 1 |
| De Angelis, C; Ekinci, E; Flajc, G; Liu, X; Rascon, K; Trivedi, MV | 1 |
| Chen, IC; Lu, YS; Yang, MH | 1 |
| Huang, HW; Huang, LS; Li, XY; Lin, JZ; Wang, HB; Xu, QN | 1 |
| Amoroso, V; Barni, S; Berruti, A; Borgonovo, K; Cabiddu, M; Ghidini, A; Ghilardi, M; Parati, MC; Pedersini, R; Petrelli, F | 1 |
| Allen, RJ; Bishop, RT; de Ridder, D; Idris, AI; Lefley, DV; Marino, S; Ottewell, PD; Sims, AH; Wang, N | 1 |
| Long, EF; Zhang, B | 1 |
| Degenhardt, T; Eggersmann, TK; Gluz, O; Harbeck, N; Wuerstlein, R | 1 |
| DuRoss, AN; Eaton, CT; Landry, MR; Neufeld, MJ; Rosch, JG; Sahay, G; Sun, C; Thomas, CR | 1 |
| Arteaga, CL; Balko, JM; Bardia, A; Bauer, JA; Behdad, A; Cristofanilli, M; Croessmann, S; Cruz, MR; Dugger, TC; Ericsson, PG; Formisano, L; Guerrero-Zotano, AL; Guo, Y; Hanker, AB; He, W; Jansen, VM; Lanman, RB; Lee, KM; Lu, Y; Mayer, IA; Miller, M; Nagy, RJ; Nixon, MJ; O'Shaughnessy, J; Sanders, ME; Schwarz, LJ; Servetto, A; Shyr, Y; Solovieff, N; Su, F; Sudhan, DR | 1 |
| Chen, Q; Dai, Y; Guo, Q; Lin, X; Xu, R; Ye, L; Zhang, Y | 1 |
| Cai, Z; Enatsu, S; Ishiguro, H; Omori, Y | 1 |
| Cheng, Y; Cristofanilli, M; Cui, S; Feng, J; Gao, J; Geng, C; Gu, K; Hu, X; Jiang, Z; Li, W; Liu, T; Lu, X; Ning, Z; Ouyang, Q; Ouyang, T; Pan, Y; Sun, T; Sun, Y; Tong, Z; Wang, H; Wang, S; Wang, X; Yin, Y; Zhang, Q | 1 |
| D'Angelillo, RM; Dell'Aquila, E; Fiore, M; Greco, C; Ippolito, E; Petrianni, GM; Ramella, S; Silipigni, S; Tonini, G | 1 |
| Bardia, A; Campos-Gomez, S; Chakravartty, A; Chow, L; Colleoni, M; Franke, F; Gounaris, I; Harbeck, N; Hughes, G; Hurvitz, S; Im, SA; Jung, KH; Lee, KS; Lu, YS; Rodriguez-Lorenc, K; Sohn, J; Taran, T; Tripathy, D; Villanueva-Vazquez, R | 1 |
| Andrews, C; Bardia, A; Barry, WT; Goel, S; Mayer, EL; Pernas, S; Rees, R; Spring, LM; Tahara, RK; Tan-Wasielewski, Z; Tolaney, SM; Trippa, L; Winer, EP | 1 |
| Harada, M; Iida, Y; Inao, T; Kartika, ID; Kotani, H; Okimoto, T; Shiba, E; Tanino, R | 1 |
| Yardley, DA | 1 |
| Al-Showbaki, LN; Alqaisi, HA; Awidi, AS; Awidi, MA; Bawa'neh, HS; El Khatib, OH; Khalil, LT; Mansour, AT | 1 |
| Rugo, HS | 1 |
| Biskupiak, J; Brixner, D; Dalal, AA; Oderda, G; Tang, D; Zacker, C | 1 |
| Cersosimo, RJ | 1 |
| Hu, X; Sharma, S; Wang, MH; Yao, HP; Zeng, JY; Zhang, R; Zhou, YQ; Zhuang, CM | 1 |
| Antón, P; Arribas, J; Baselga, J; Eichhorn, PJ; García-García, C; Hahn, WC; Ibrahim, YH; Kim, SY; Marlow, S; Parra, JL; Pérez-Garcia, J; Prat, A; Prudkin, L; Rodríguez, O; Sánchez, G; Scaltriti, M; Serra, V | 1 |
| Chen, X; Hao, M; Liu, J; Mao, Y; Shen, K; Shen, Y; Sun, X; Wang, J; Zhao, M; Zu, L | 1 |
| Wang, Q; Weisberg, E; Zhao, JJ | 1 |
| Sharma, S; Wang, MH; Yao, HP; Zhang, R; Zhou, J; Zhou, YQ | 1 |
| Arteaga, CL; Chanthaphaychith, S; Dahlman, K; Rexer, BN | 1 |
| Abramson, VG; Arteaga, CL; Balko, JM; Cantley, LC; Forero, A; Isakoff, SJ; Kuba, MG; Li, Y; Mayer, IA; Sanders, ME; Van den Abbeele, AD; Winer, E; Yap, JT | 1 |
| Das, S; De Chatterjee, A; Guevara, P; Metta-Magaña, AJ; Nuñez, JE; Ramirez, V; Varela, JG; Varela-Ramirez, A; Villagrán, D | 1 |
| Dedes, KJ; Fink, D; Gutsche, K; Imesch, P; Samartzis, EP; Stucki, M | 1 |
| Brower, V | 1 |
| Abramson, V; Arteaga, CL; Balko, JM; Estrada, MV; Fox, EM; Garrett, JT; González-Angulo, AM; Kelley, MC; Kuba, MG; Mayer, IA; Meszoely, IM; Mills, GB; Red-Brewer, M; Rizzo, M; Schwarz, LJ | 1 |
| Aversa, C; Geuna, E; Martinello, R; Milani, A; Montemurro, F; Scaltriti, M; Valabrega, G | 1 |
| Mayer, EL | 2 |
| Choi, HJ; Choi, JW; Jang, KS; Kang, JH; Kim, HY; Kim, S; Kong, G; Lee, JY; Oh, SH; Oh, YH; Park, JH; Shin, DH; Son, T; Won, HY; Woo, JK; Yi, K | 1 |
| Dickler, MN; Murphy, CG | 1 |
| Dawood, S; Rastogi, S; Sirohi, B | 1 |
| Lorimer, E; Tyburski, MD; Williams, CL; Wilson, JM | 1 |
| Rugo, HS; Vidula, N | 1 |
| Estévez, LG; García, E; Hidalgo, M | 1 |
| Kimura-Tsuchiya, R; Saji, S; Sasaki, E | 1 |
| Ademuyiwa, F; Ellis, MJ; Griffith, M; Griffith, OL; Guo, Z; Han, J; Hoog, J; Lockhart, C; Luo, J; Ma, CX; Mardis, E; Nagaraj, G; Naughton, M; Pluard, T; Ramu, A; Skidmore, ZL; Spies, NC; Suresh, R; Thomas, S; Trani, L | 1 |
| Konecny, GE | 1 |
| Guo, R; Hu, Y; Ji, W; Liu, J; Wei, J; Zhang, J; Zhi, X; Zhou, Y | 1 |
| Benada, J; Burdova, K; Jenikova, G; Kleiblova, P; Macurek, L; Pechackova, S | 1 |
| Braun, GB; Chung, TD; Kotamraju, VR; Paasonen, L; Pellecchia, M; Ruoslahti, E; Sharma, S; She, ZG; Sugahara, KN; Teesalu, T; Wu, B; Yliperttula, M | 1 |
| Finn, RS; O'Leary, B; Turner, NC | 1 |
| Beckmann, RP; Beeram, M; Chan, EM; Cronier, DM; Flaherty, KT; Frenzel, M; Fulford, AD; Gandhi, L; Goldman, JW; Hilton, JF; Kulanthaivel, P; Li, LQ; Martinez, R; Nasir, A; Nguyen, TS; Papadopoulos, KP; Patnaik, A; Rasco, DW; Rosen, LS; Schade, AE; Shapiro, GI; Tolaney, SM; Tolcher, AW; Wen, PY | 1 |
| Alexander, BM; Claus, EB; Du, R; Goel, S; Guo, H; Hayashi, M; Iglehart, JD; Kang, YJ; Krop, IE; Ligon, AH; Ligon, KL; Lin, NU; Luu, V; Marco, E; Nguyen, QD; Ni, J; Ramkissoon, LA; Ramkissoon, SH; Roberts, TM; Stover, DG; Wang, ZC; Winer, EP; Xie, S; Yuan, GC; Zhao, JJ | 1 |
| O'Sullivan, CC | 1 |
| Bardia, A; Beck, JT; Conte, P; Curigliano, G; Dhuria, S; Di Tomaso, E; Gómez Pardo, P; Hurvitz, SA; Lolkema, MP; Martínez García, M; Meric-Bernstam, F; Miller, M; Penault-Llorca, F; Solovieff, N; Tang, Z | 1 |
| Lim, JS; Turner, NC; Yap, TA | 1 |
| Liu, P; Xu, B; Zhang, C | 1 |
| Alba, E; André, F; Arteaga, CL; Bachelot, T; Blackwell, KL; Blau, S; Burdaeva, O; Burris, HA; Cameron, DA; Campone, M; Chan, A; Conte, P; Favret, AM; Germa, C; Grischke, EM; Hart, LL; Hirawat, S; Hortobagyi, GN; Jakobsen, E; Janni, W; Marschner, N; Miller, M; Nusch, A; O'Shaughnessy, J; Paluch-Shimon, S; Petrakova, K; Sonke, GS; Souami, F; Stemmer, SM; Tseng, LM; Verma, S; Villanueva, C; Winer, EP; Wist, E; Xuan, F; Yap, YS; Yardley, D | 1 |
| Burki, TK | 1 |
| Baselga, J; Bhatt, T; Chandarlapaty, S; Dickler, M; Giri, D; Li, Z; Rosen, N; Scaltriti, M; Yang, C | 1 |
| Batista López, N; Beck, JT; Campone, M; Chan, A; Delaloge, S; Di Tomaso, E; Dirix, L; Goteti, S; Hegg, R; Khan, QJ; Krivorotko, P; Manikhas, A; Martín, M; Massacesi, C; O'Shaughnessy, J; Ramos Vázquez, M; Ruiz Borrego, M; Shtivelband, M; Urban, P | 1 |
| Aghajanian, C; Barry, WT; Bell-McGuinn, KM; Berger, MF; Birrer, M; Cantley, LC; Farooq, S; Hok, RC; Liu, H; Liu, J; Luo, W; Matulonis, UA; Mills, GB; Obermayer, E; Palakurthi, S; Solit, DB; Spagnoletti, T; Taylor, BS; Westin, SN; Whalen, C; Winer, E; Won, H; Wulf, GM | 1 |
| Ju, W; Kim, CY; Kim, HJ; Kim, SC; Kim, YH; Lee, SY | 1 |
| Basse, C; Dieras, V; Jobard, A; Le Tourneau, C; Loirat, D; Ricci, F; Romano, E; Sablin, MP | 1 |
| Arteaga, CL; Bauer, JA; Bhola, NE; Dugger, TC; Ericsson, PG; Estrada, MV; Formisano, L; Hutchinson, KE; Jansen, VM; Knudsen, ES; Lee, KM; Moore, PD; Pishvaian, MJ; Pohlmann, PR; Riddle, DA; Sánchez, V; Sanders, ME; Wei, W; Witkiewicz, AK | 1 |
| Kwok, C; Luo, H; McMahon, G; Nam, JO; Patel, N; Phillips, A; Schlaepfer, DD; Stupack, DG; Tanjoni, I; Tomar, A; Uryu, S; Walsh, C | 1 |
| Conti, AA; Dilaghi, B; Modesti, PA; Nozzoli, C | 1 |
| Crowder, RJ; Ellis, MJ; Gao, F; Guintoli, T; Lin, L; Ma, CX; Phommaly, C; Sanchez, CG | 1 |
| Hong, S; Kim, J | 1 |
| Appert, HE; Bartsch, JE; Staren, ED | 1 |
87 review(s) available for alpha-aminopyridine and Breast Neoplasms
| Article | Year |
|---|---|
Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Chemotherapy, Adjuvant; Consensus; Disease-Free Survival; Female; Humans; Medical Oncology; Neoplasm Staging; Protein Kinase Inhibitors; Time Factors | 2022 |
[Development of CDK4 & 6 Inhibitor Abemaciclib in Breast Cancer].
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Humans; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2021 |
Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Humans; Piperazines; Prognosis; Purines; Pyridines | 2022 |
Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside.
Topics: Aminopyridines; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Lung Neoplasms; Neuroendocrine Tumors; Protein Kinase Inhibitors; Small Cell Lung Carcinoma | 2022 |
Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Female; Humans; Patient Reported Outcome Measures; Purines; Quality of Life; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2022 |
Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity.
Topics: Aminopyridines; Breast Neoplasms; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Protein Kinase Inhibitors; Quality of Life | 2022 |
Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogens; Female; Humans; Mitogens; Protein Kinase Inhibitors; Tumor Suppressor Proteins | 2022 |
Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review.
Topics: Aminopyridines; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Protein Kinase Inhibitors; Quality of Life | 2022 |
Cyclin-dependent kinase 4/6 inhibitor-associated thromboembolism: a critical evaluation of the current evidence.
Topics: Aminopyridines; Anticoagulants; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Humans; Protein Kinase Inhibitors; Pyridines; Venous Thromboembolism | 2023 |
Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Receptor, ErbB-2 | 2023 |
Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Adjuvants, Immunologic; Adult; Aminopyridines; Benzimidazoles; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; State Medicine; Technology Assessment, Biomedical | 2023 |
Advances in pharmacotherapies that target the cell cycle for treatment of breast cancer: where are we at today?
Topics: Aminopyridines; Breast Neoplasms; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyridines | 2023 |
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Receptor, ErbB-2 | 2023 |
HR+/HER2- Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review.
Topics: Aged; Aminopyridines; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local | 2023 |
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences.
Topics: Aminopyridines; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Humans | 2023 |
Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Protein Kinase Inhibitors; Receptor, ErbB-2; Triple Negative Breast Neoplasms | 2023 |
Mechanism of CDK4/6 Inhibitor Resistance in Hormone Receptor-positive Breast Cancer and Alternative Treatment Strategies.
Topics: Aminopyridines; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor Proteins; Female; Humans; Protein Kinase Inhibitors | 2023 |
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Cycle Checkpoints; Cyclin-Dependent Kinases; Drug Discovery; Humans; Indoles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Pyrimidines; Transcription Factors | 2019 |
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Paclitaxel; Piperazines; Postmenopause; Progression-Free Survival; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Japan; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines | 2019 |
The efficacy and safety of neoadjuvant buparlisib for breast cancer: A meta-analysis of randomized controlled studies.
Topics: Aminopyridines; Breast Neoplasms; Humans; Morpholines; Neoadjuvant Therapy; Phosphoinositide-3 Kinase Inhibitors; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2019 |
[2019 international oncology news: A compendium].
Topics: Aminopyridines; Breast Neoplasms; Clinical Trials as Topic; Digestive System Neoplasms; Female; Genital Neoplasms, Female; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms; Purines | 2020 |
The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC).
Topics: Alopecia; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogen Receptor alpha; Female; Fulvestrant; Germany; Humans; Incidence; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Progesterone; Survival Rate; Tamoxifen | 2020 |
Increased risk of cardiac conduction abnormalities with ribociclib in patients with metastatic breast cancer: A combined analysis of phase III randomized controlled trials.
Topics: Aminopyridines; Breast Neoplasms; Cardiac Conduction System Disease; Clinical Trials, Phase III as Topic; Female; Humans; Neoplasm Metastasis; Purines; Randomized Controlled Trials as Topic; Risk Factors | 2021 |
Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Cell Cycle Checkpoints; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Protein Kinase Inhibitors; Quality of Life | 2020 |
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer.
Topics: Aminopyridines; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Molecular Targeted Therapy; Prognosis; Protein Kinase Inhibitors; Treatment Outcome | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Neoplasm Metastasis; Network Meta-Analysis; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic | 2020 |
Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines | 2020 |
Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quality of Life | 2021 |
Ribociclib plus fulvestrant in the treatment of breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Fulvestrant; Humans; Progression-Free Survival; Purines; Randomized Controlled Trials as Topic; Survival Rate | 2021 |
Risk-adapted adjuvant therapy of luminal early breast cancer in 2020.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Benzimidazoles; Breast Neoplasms; COVID-19; Female; Gene Expression Profiling; Humans; Ki-67 Antigen; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; SARS-CoV-2 | 2021 |
Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis.
Topics: Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Female; Humans; Morpholines; Mutation; Network Meta-Analysis; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Progression-Free Survival; Signal Transduction; Thiazoles; Treatment Outcome | 2020 |
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Topics: Aminopyridines; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Trastuzumab | 2021 |
[Targeting the cyclin-dependent kinases 4/6 in advanced breast cancers].
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cell Cycle; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Retinoblastoma Binding Proteins; Ubiquitin-Protein Ligases | 2021 |
CDK4/6 inhibitor-induced colitis: a case report and review of the literature.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colitis; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Letrozole; Purines; Receptor, ErbB-2; Receptors, Estrogen | 2021 |
HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.
Topics: Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Liver; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Transcription Factors | 2017 |
Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Purines; Receptor, ErbB-2 | 2017 |
Recent advances of highly selective CDK4/6 inhibitors in breast cancer.
Topics: Aminopyridines; Antineoplastic Agents, Immunological; Benzimidazoles; Breast Neoplasms; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Screening Assays, Antitumor; Female; Humans; Molecular Targeted Therapy; Neoplasm Proteins; Piperazines; Purines; Pyridines; Therapies, Investigational | 2017 |
Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Molecular Targeted Therapy; Neutropenia; Piperazines; Purines; Pyridines | 2017 |
A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Triazoles | 2017 |
Treatment for the endocrine resistant breast cancer: Current options and future perspectives.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Everolimus; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Morpholines; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction | 2017 |
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Interactions; Female; Humans; Molecular Targeted Therapy; Neutropenia; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines | 2017 |
Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Evaluation, Preclinical; Female; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2017 |
Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic | 2017 |
Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Metastasis; Neutropenia; Postmenopause; Purines; Receptor, ErbB-2 | 2017 |
Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinases; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Risk Assessment; Triazoles | 2017 |
CDK4/6 blockade in breast cancer: current experience and future perspectives.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Design; Female; Humans; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines | 2017 |
Abemaciclib: First Global Approval.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinases; Drug Approval; Estradiol; Female; Fulvestrant; Humans; Neoplasm Metastasis; United States; United States Food and Drug Administration | 2017 |
Clinical development of CDK4/6 inhibitor for breast cancer.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptors, Estrogen | 2018 |
Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Design; Female; Humans; Neoplasm Metastasis; Progression-Free Survival; Purines | 2018 |
Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
Topics: Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Postmenopause; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Hormone Antagonists; Humans; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Treatment Outcome | 2018 |
Abemaciclib for the treatment of breast cancer.
Topics: Aminopyridines; Benzimidazoles; Biomarkers; Brain Neoplasms; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Therapy, Combination; Estradiol; Female; Fulvestrant; Humans; Neoplasm Staging; Prognosis | 2018 |
Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference?
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Purines; Pyridines | 2018 |
Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen | 2018 |
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Forecasting; Humans; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Treatment Outcome | 2019 |
Current frontline endocrine treatment options for women with hormone receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced-stage breast cancer.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Neoplasm Staging; Piperazines; Purines; Pyridines; Receptor, ErbB-2 | 2019 |
CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines | 2018 |
Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Synergism; Humans; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen | 2017 |
CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Humans; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines | 2017 |
Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
Topics: Aminopyridines; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease Progression; Female; Humans; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2 | 2019 |
Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Chemotherapy-Induced Febrile Neutropenia; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2019 |
An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Piperazines; Progression-Free Survival; Protein Kinase Inhibitors; Purines; Pyridines | 2018 |
Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Models, Economic; Purines; Randomized Controlled Trials as Topic; Receptors, Estrogen; Technology Assessment, Biomedical | 2019 |
Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment.
Topics: Aminopyridines; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Lymphocytes, Tumor-Infiltrating; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptors, Estrogen; Tumor Microenvironment | 2019 |
Targeting CDK4/6 pathways and beyond in breast cancer.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Humans; Molecular Targeted Therapy; Piperazines; Progression-Free Survival; Protein Kinase Inhibitors; Purines; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction | 2019 |
CDK4-6 inhibitors in breast cancer: current status and future development.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Progression-Free Survival; Protein Kinase Inhibitors; Purines; Pyridines | 2018 |
Treatment of advanced HR+/HER2- breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Disease Progression; Drugs, Investigational; Everolimus; Female; Humans; Molecular Targeted Therapy; Piperazines; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Cytoplasmic and Nuclear; Treatment Outcome | 2019 |
The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Asian People; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Progression-Free Survival; Protein Kinase Inhibitors; Purines; Pyridines | 2019 |
Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Humans; Neoplasm Metastasis; Premenopause; Purines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen | 2019 |
Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Protein Kinase Inhibitors | 2019 |
CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A network meta-analysis.
Topics: Aminopyridines; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; ErbB Receptors; Everolimus; Female; Fulvestrant; Humans; Network Meta-Analysis; Piperazines; Postmenopause; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; TOR Serine-Threonine Kinases | 2019 |
Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Piperazines; Prospective Studies; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptors, Estrogen; Survival Analysis; Treatment Outcome | 2019 |
CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic | 2019 |
Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Piperazines; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Dose-Response Relationship, Drug; Fatigue; Female; Gastrointestinal Diseases; Humans; Molecular Targeted Therapy; Neoplasm Staging; Neutropenia; Piperazines; Progression-Free Survival; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic | 2019 |
Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction | 2015 |
Targeting breast cancer with CDK inhibitors.
Topics: Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines | 2015 |
The Role of CDK4/6 Inhibition in Breast Cancer.
Topics: Aminopyridines; Breast Neoplasms; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; DNA Breaks, Double-Stranded; Estrogen Receptor alpha; Female; Flavonoids; Humans; Piperazines; Piperidines; Protein Kinase Inhibitors; Purines; Pyridines | 2015 |
Buparlisib in breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Female; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines | 2016 |
Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Mice; Molecular Targeted Therapy; Morpholines; Phosphatidylinositol 3-Kinases; Signal Transduction | 2016 |
Cyclin-dependent kinase pathways as targets for women's cancer treatment.
Topics: Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Liposarcoma; Lymphoma, Mantle-Cell; Melanoma; Neoplasms, Germ Cell and Embryonal; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Signal Transduction | 2016 |
Treating cancer with selective CDK4/6 inhibitors.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cell Cycle; Clinical Trials as Topic; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Forecasting; Humans; Molecular Targeted Therapy; Neoplasms; Piperazines; Purines; Pyridines | 2016 |
CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2 | 2016 |
77 trial(s) available for alpha-aminopyridine and Breast Neoplasms
| Article | Year |
|---|---|
Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Double-Blind Method; Drug Resistance, Neoplasm; Female; Genomics; Humans; Middle Aged; Premenopause; Progression-Free Survival; Proportional Hazards Models; Purines; Receptor, ErbB-2; Transcription Factors; Young Adult | 2021 |
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Neoplasm Recurrence, Local; Receptor, ErbB-2 | 2021 |
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Female; Humans; Japan; Letrozole; Middle Aged; Progression-Free Survival; Quality of Life; Receptors, Progesterone | 2022 |
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Perimenopause; Purines; Receptor, ErbB-2; Receptors, Estrogen | 2022 |
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEESA-3 Trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Postmenopause; Purines | 2022 |
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Circulating Tumor DNA; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Male; Mutation; Receptor, ErbB-2 | 2022 |
Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Hormones; Humans; Letrozole; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2022 |
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Intention to Treat Analysis; Letrozole; Middle Aged; Neoplasm Grading; Neutropenia; Purines; Receptor, ErbB-2; Receptors, Estrogen; Survival Analysis | 2022 |
Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Male; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2022 |
Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Receptor, ErbB-2 | 2022 |
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Humans; Progression-Free Survival; Tamoxifen | 2022 |
An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Diarrhea; Female; Humans; Loperamide | 2022 |
Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial.
Topics: Aminopyridines; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Purines; Quality of Life; Taxoids | 2022 |
Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; East Asian People; Female; Fulvestrant; Humans; Receptor, ErbB-2 | 2023 |
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Neutropenia; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2022 |
Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Humans; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2023 |
Justifying Ribociclib Dose in Patients with Advanced Breast Cancer with Renal Impairment Based on PK, Safety, and Efficacy Data: An Innovative Approach Integrating Data from a Dedicated Renal Impairment Study and Oncology Clinical Trials.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Purines; Renal Insufficiency | 2023 |
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Female; Humans; Letrozole; Proportional Hazards Models; Prospective Studies; Receptor, ErbB-2; Thymidine Kinase | 2023 |
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
Topics: Aminopyridines; Australia; Breast Neoplasms; Cyclin D; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclins; DNA Helicases; Female; Humans; Neoplasms; Nuclear Proteins; Precision Medicine; Protein Kinase Inhibitors | 2023 |
Potential value of ctDNA monitoring in metastatic HR + /HER2 - breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Receptor, ErbB-2 | 2023 |
Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA).
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Quality of Life; Receptor, ErbB-2 | 2023 |
Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).
Topics: Aminopyridines; Antibodies; Benzimidazoles; Breast Neoplasms; Female; Humans; Letrozole; Nivolumab | 2023 |
Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Evaluation; Female; Follow-Up Studies; Humans; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Piperazines; Prognosis; Purines; Pyridines; Receptors, Estrogen; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Middle Aged; Receptor, ErbB-2; Triple Negative Breast Neoplasms | 2020 |
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Postmenopause; Progression-Free Survival; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2020 |
Cyclin-dependent kinase inhibitors plus aromatase inhibitor in first-line treatment hormone-receptor-positive/HER2-negative advanced breast cancer women with or without visceral disease: time to turn page?
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Prognosis; Purines; Pyridines; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Viscera | 2020 |
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen | 2020 |
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Topics: Aged; Aminopyridines; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Argentina; Australia; Benzimidazoles; Brazil; Breast Neoplasms; Disease Progression; Estrogen Receptor Antagonists; Europe; Female; Fulvestrant; Humans; Middle Aged; North America; Progression-Free Survival; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Republic of Korea; Signal Transduction; Time Factors; Trastuzumab | 2020 |
Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Female; Humans; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen | 2020 |
Development and Application of a Mechanistic Population Modeling Approach to Describe Abemaciclib Pharmacokinetics.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Case-Control Studies; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Compounding; Drug Development; Female; Humans; Male; Middle Aged; Nonlinear Dynamics; Protein Kinase Inhibitors | 2020 |
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer.
Topics: Adult; Aged; Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Mice; Middle Aged; Protein Kinase Inhibitors; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab | 2020 |
Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Healthy Subjects.
Topics: Administration, Oral; Adult; Aminopyridines; Biological Availability; Breast Neoplasms; Cross-Over Studies; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Compounding; Female; Healthy Volunteers; Humans; Infusions, Intravenous; Male; Middle Aged; Purines; Receptor, ErbB-2; Safety; Severity of Illness Index; Therapeutic Equivalency | 2020 |
Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Benzimidazoles; Body Mass Index; Breast Neoplasms; Confidence Intervals; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Middle Aged; Neutropenia; Obesity; Odds Ratio; Overweight; Placebos; Progression-Free Survival; Thinness; Weight Loss | 2021 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Young Adult | 2020 |
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Health Status; Humans; Kaplan-Meier Estimate; Middle Aged; Patient Reported Outcome Measures; Progression-Free Survival; Proportional Hazards Models; Purines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2020 |
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.
Topics: Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Metastasis; Prognosis; Progression-Free Survival; Tamoxifen; Treatment Outcome | 2021 |
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.
Topics: Age Factors; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Receptor, ErbB-2 | 2021 |
Abemaciclib Improves Disease-Free Survival in High-Risk HR+/HER2- Early Breast Cancer.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Disease-Free Survival; Female; Humans; Receptor, ErbB-2 | 2021 |
Drug shows significant early promise in early, high-risk, HR-positive, HER2-negative breast cancer: Interim data indicate that adding abemaciclib to hormonal therapy reduces recurrence risk.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Drug Therapy, Combination; Female; Hormone Replacement Therapy; Humans; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Estrogen | 2021 |
Pharmacokinetics of Ribociclib in Subjects With Hepatic Impairment.
Topics: Aminopyridines; Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Female; Half-Life; Humans; Liver Diseases; Male; Metabolic Clearance Rate; Middle Aged; Patient Acuity; Purines | 2021 |
First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Breast Neoplasms; China; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Humans; Markov Chains; Premenopause; Purines; Quality-Adjusted Life Years; Receptor, ErbB-2; United States | 2021 |
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Topics: Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Fulvestrant; Humans; Letrozole; Neutropenia; Receptor, ErbB-2; Treatment Outcome | 2021 |
Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients.
Topics: Adult; Age Factors; Aged; Aminopyridines; Antineoplastic Agents; Area Under Curve; Body Weight; Breast Neoplasms; Drug Interactions; Female; Humans; Kidney Function Tests; Liver Function Tests; Male; Metabolic Clearance Rate; Metabolic Networks and Pathways; Middle Aged; Models, Biological; Neoplasm Metastasis; Neutrophils; Purines; Racial Groups; Receptor, ErbB-2; Receptors, Progesterone; Sex Factors | 2021 |
Patient-Reported Outcomes Predict Progression-Free Survival of Patients with Advanced Breast Cancer Treated with Abemaciclib.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Humans; Patient Reported Outcome Measures; Progression-Free Survival; Receptor, ErbB-2 | 2021 |
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
Topics: Adolescent; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Postmenopause; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2021 |
Ribociclib Shows Sustained Overall Survival Benefit in Postmenopausal Women with HR+/HER2- Advanced Breast Cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Postmenopause; Purines; Receptor, ErbB-2; Receptors, Progesterone | 2021 |
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Drug Tapering; Female; Humans; Middle Aged; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Young Adult | 2021 |
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; MCF-7 Cells; Menopause; Middle Aged; Neoadjuvant Therapy; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Transcriptome | 2021 |
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Purines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2021 |
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
Topics: Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Middle Aged; Premenopause; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2021 |
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Alanine Transaminase; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Double-Blind Method; Drug Eruptions; Estradiol; Exanthema; Female; Fulvestrant; Humans; Hyperglycemia; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Retreatment; Signal Transduction; Survival Rate | 2017 |
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2017 |
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Australia; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Double-Blind Method; Early Termination of Clinical Trials; Europe; Female; Humans; Ki-67 Antigen; Lymphocytes, Tumor-Infiltrating; Middle Aged; Morpholines; Mutation; Neoadjuvant Therapy; Paclitaxel; Protein Kinase Inhibitors; Receptor, ErbB-2; Time Factors; Trastuzumab; Treatment Outcome | 2017 |
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Dosage Calculations; Drug Resistance, Neoplasm; Female; France; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptor, ErbB-2; Survival Rate; Treatment Outcome; Triazoles | 2017 |
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Middle Aged; Nitriles; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2018 |
A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.
Topics: Adult; Aminopyridines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Treatment Outcome | 2018 |
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Chemotherapy-Induced Febrile Neutropenia; Female; Humans; Incidence; Kaplan-Meier Estimate; Letrozole; Leukopenia; Middle Aged; Postmenopause; Progression-Free Survival; Purines; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Time Factors | 2018 |
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Maximum Tolerated Dose; Middle Aged; Morpholines; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Trastuzumab | 2018 |
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Disease-Free Survival; Double-Blind Method; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome | 2018 |
First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Purines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Young Adult | 2018 |
Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Postmenopause; Purines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Young Adult | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Female; Follow-Up Studies; Humans; Letrozole; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Recurrence, Local; Prognosis; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate | 2018 |
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Topics: Administration, Oral; Adult; Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Internationality; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Premenopause; Prognosis; Proportional Hazards Models; Purines; Survival Analysis; Tamoxifen; Treatment Outcome; Young Adult | 2018 |
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Progression-Free Survival; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2018 |
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Middle Aged; Morpholines; Postmenopause; Survival Analysis | 2018 |
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aminopyridines; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Breast Neoplasms; Double-Blind Method; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Salvage Therapy; Survival Rate; Treatment Outcome | 2019 |
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
Topics: Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclin-Dependent Kinases; Double-Blind Method; Female; Follow-Up Studies; Humans; Intention to Treat Analysis; Middle Aged; Perimenopause; Premenopause; Protein Kinase Inhibitors; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Tamoxifen | 2019 |
Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Female; Follow-Up Studies; Humans; Middle Aged; Prognosis; Purines; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2019 |
MONALEESA clinical program: a review of ribociclib use in different clinical settings.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogens; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Postmenopause; Progression-Free Survival; Purines; Receptor, ErbB-2; Tamoxifen; Young Adult | 2019 |
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Humans; Letrozole; Middle Aged; Morpholines; Multimodal Imaging; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiopharmaceuticals; Receptor, ErbB-2; Receptors, Estrogen; Tomography, X-Ray Computed; Triazoles | 2014 |
LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
Topics: Amino Acid Substitution; Aminopyridines; Animals; Breast Neoplasms; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Estrogen Receptor Modulators; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Morpholines; Mutation, Missense; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Receptors, Estrogen; src Homology Domains; src-Family Kinases; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin D2; Cyclin D3; Cyclin E; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; DNA, Neoplasm; Female; Gene Expression; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Oncogene Proteins; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retinoblastoma Protein; Signal Transduction; Triazoles | 2016 |
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2016 |
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Morpholines; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Proportional Hazards Models; Receptor, ErbB-2; Treatment Outcome; Young Adult | 2017 |
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
Topics: Adult; Aged; Aminopyridines; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Germ-Line Mutation; Humans; Middle Aged; Morpholines; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2017 |
204 other study(ies) available for alpha-aminopyridine and Breast Neoplasms
| Article | Year |
|---|---|
Assessment of Transporter-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Topics: Aged; Aminopyridines; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Digoxin; Drug Interactions; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Membrane Transport Proteins; Myelodysplastic Syndromes; Neoplasm Proteins; Pharmaceutical Preparations; Recurrence; Rosuvastatin Calcium; Triazines | 2022 |
Safety of cyclin-dependent kinase4/6 inhibitor combined with palliative radiotherapy in patients with metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Protein Kinase Inhibitors; Pyridines; Retrospective Studies | 2021 |
[A Case of Advanced Late Recurrence of Hormone Receptor Positive Breast Cancer Successfully Treated with Abemaciclib and Anastrozole].
Topics: Aged; Aminopyridines; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Female; Hormones; Humans; Neoplasm Recurrence, Local; Nitriles | 2021 |
Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Fatal Outcome; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Peritoneal Neoplasms | 2021 |
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Chromatography, Liquid; Dried Blood Spot Testing; Drug Monitoring; Female; Humans; Letrozole; Piperazines; Purines; Pyridines; Tandem Mass Spectrometry | 2021 |
Lactic acidosis, a potential toxicity from drug-drug interaction related to concomitant ribociclib and metformin in preexisting renal insufficiency: A case report.
Topics: Acidosis, Lactic; Aminopyridines; Breast Neoplasms; Drug Interactions; Female; Fulvestrant; Humans; Metformin; Middle Aged; Purines; Renal Insufficiency | 2022 |
Letter to the Editor for 'Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study'.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Female; Humans; Ki-67 Antigen | 2022 |
Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Carrier Proteins; Crystallography, X-Ray; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Dyrk Kinases; Female; Gene Expression Regulation; Humans; Intracellular Signaling Peptides and Proteins; Phosphorylation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Ribosomal Proteins; RNA-Binding Proteins; Signal Transduction | 2021 |
Adjuvant abemaciclib for high-risk breast cancer: the story continues.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Female; Humans | 2021 |
Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Humans; Ki-67 Antigen | 2022 |
Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Immunity; Leukocytes, Mononuclear; Purines; Receptor, ErbB-2 | 2022 |
Amalgamated Microneedle Array Bearing Ribociclib-Loaded Transfersomes Eradicates Breast Cancer
Topics: Aminopyridines; Breast Neoplasms; Drug Delivery Systems; Female; Humans; Hyaluronan Receptors; Purines | 2022 |
FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer.
Topics: Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Receptor, ErbB-2 | 2022 |
Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Japan; Middle Aged; Neoplasm Metastasis; Piperazines; Progression-Free Survival; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Treatment Outcome | 2022 |
In brief: Abemaciclib (Verzenio) for early breast cancer.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Female; Humans | 2021 |
Ribociclib Nanostructured Lipid Carrier Aimed for Breast Cancer: Formulation Optimization, Attenuating
Topics: Administration, Oral; Aminopyridines; Animals; Biological Availability; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Excipients; Female; Intestinal Absorption; Nanostructures; Purines; Rats; Rats, Wistar | 2022 |
Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor Proteins; Female; Humans; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Tumor Microenvironment | 2022 |
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Receptor, ErbB-2 | 2022 |
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Diarrhea; Female; Humans; Neoplasm Recurrence, Local; Patient Reported Outcome Measures; Quality of Life; Receptor, ErbB-2 | 2022 |
Ribociclib Improves Overall Survival in HR+/HER2- Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes.
Topics: Aminopyridines; Breast Neoplasms; Female; Genomics; Humans; Purines | 2022 |
Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A.
Topics: Aminopyridines; Benzimidazoles; Breast; Breast Neoplasms; Female; Humans | 2022 |
Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Humans | 2022 |
Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Drug Interactions; Female; Fulvestrant; Humans; Letrozole; Piperazines; Protein Kinase Inhibitors; Proton Pump Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Retrospective Studies | 2022 |
Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib.
Topics: Aminopyridines; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzimidazoles; Breast Neoplasms; Female; Genotype; Humans; Polymorphism, Single Nucleotide | 2022 |
Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Female; Fulvestrant; Humans; Paclitaxel; Piperazines; Postmenopause; Purines; Pyridines | 2022 |
Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Incidence; Protein Kinase Inhibitors; Retrospective Studies; United States | 2022 |
Vortex keratopathy associated with ribociclib.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Purines; Receptor, ErbB-2 | 2023 |
[A Case of Postoperative Pulmonary Metastasis of Breast Cancer with Complete Response by Abemaciclib plus Fulvestrant Therapy].
Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Lung Neoplasms; Mastectomy; Neoplasm Recurrence, Local | 2022 |
Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2022 |
Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer.
Topics: Aminopyridines; Anticoagulants; Benzimidazoles; Breast Neoplasms; Female; Humans; Thrombosis; Venous Thromboembolism | 2022 |
Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors | 2022 |
CDK4/6 inhibitors downregulate the ubiquitin-conjugating enzymes UBE2C/S/T involved in the ubiquitin-proteasome pathway in ER + breast cancer.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Hormones; Humans; Phosphatidylinositol 3-Kinases; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Purines; RNA, Messenger; Ubiquitin-Conjugating Enzymes; Ubiquitins | 2022 |
Abemaciclib and Fulvestrant for Bilateral Choroidal Metastasis From Breast Carcinoma.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans | 2022 |
Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2- Advanced Breast Cancer Patients: An Italian Managed Access Program.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Gonadotropin-Releasing Hormone; Humans; Purines; Receptor, ErbB-2; Receptors, Estrogen | 2022 |
Quantifying Clinical Utility of Adjuvant Abemaciclib in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy-Reply.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Neoadjuvant Therapy; Receptor, ErbB-2 | 2022 |
Quantifying Clinical Utility of Adjuvant Abemaciclib in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Neoadjuvant Therapy; Receptor, ErbB-2 | 2022 |
The Cyclin-Dependent Kinase 4/6 Inhibitor Abemaciclib Is Tolerated Better than Palbociclib by Advanced Breast Cancer Patients with High Serum Albumin Levels.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Retrospective Studies; Serum Albumin | 2022 |
Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors.
Topics: Aminopyridines; Benzimidazoles; Biomarkers; Breast Neoplasms; C-Reactive Protein; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Lymphocyte Count; Lymphocytes; Prognosis; Protein Kinase Inhibitors; Receptors, Estrogen; Retrospective Studies | 2022 |
Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2022 |
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Estrogens; Female; Humans; Proton Pump Inhibitors; Retrospective Studies | 2022 |
Clinical features of CDK4/6 inhibitor-related interstitial lung disease in patients with breast cancer: a case series study.
Topics: Aminopyridines; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Middle Aged; Protein Kinase Inhibitors; Retrospective Studies | 2023 |
The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Protein Kinase Inhibitors; Proton Pump Inhibitors; Purines | 2023 |
[Expert consensus on the management of adverse events of CDK4/6 inhibitors in breast cancer].
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Consensus; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Protein Kinase Inhibitors | 2022 |
Therapeutic drug monitoring in breast cancer therapy - LC-MS/MS method for quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, ribociclib, and major metabolites abemaciclib M20 and M2 in human serum.
Topics: Aminopyridines; Breast Neoplasms; Chromatography, Liquid; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Monitoring; Female; Humans; Protein Kinase Inhibitors; Tandem Mass Spectrometry | 2023 |
Ribociclib-induced hepatotoxicity.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Protein Kinase Inhibitors; Purines | 2023 |
Abemaciclib-associated Diarrhea: An Exploratory Analysis of Real-life Data.
Topics: Aged; Aminopyridines; Benzimidazoles; Breast Neoplasms; Diarrhea; Female; Humans | 2023 |
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Female; Humans; Immunologic Factors | 2023 |
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer - Authors' reply.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Female; Humans; Immunologic Factors | 2023 |
Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Fulvestrant; Humans; Male; Receptor, ErbB-2; Retrospective Studies | 2023 |
In brief: A new indication for abemaciclib (Verzenio).
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Humans; Receptor, ErbB-2 | 2023 |
US Food and Drug Administration Expanded Adjuvant Indication of Abemaciclib in High-Risk Early Breast Cancer.
Topics: Adjuvants, Immunologic; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Pyridines; United States; United States Food and Drug Administration | 2023 |
Letter to the Editor: statistics and clinical perception of patients' reported outcomes for palbociclib and abemaciclib: a sliding doors story.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Perception; Pyridines | 2023 |
Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer - Authors' reply.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Humans | 2023 |
Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Humans; Receptor, ErbB-2 | 2023 |
Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Japan; Middle Aged; Receptor, ErbB-2 | 2023 |
Clinical Management of Potential Toxicity of Abemaciclib and Approaches to Ensure Treatment Continuation.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Humans; Neutropenia; Treatment Outcome | 2023 |
Quantitative Assessment of Ribociclib Exposure-Response Relationship to Justify Dose Regimen in Patients with Advanced Breast Cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neutropenia; Purines; Receptor, ErbB-2 | 2023 |
[ESR1 Mutation-Positive Recurrent Breast Cancer Successfully Treated with Letrozole plus Abemaciclib].
Topics: Aminopyridines; Breast Neoplasms; Female; Humans; Letrozole; Mutation | 2023 |
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Prospective Studies; Receptor, ErbB-2 | 2023 |
CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease Management; Female; Follow-Up Studies; Humans; Middle Aged; Piperazines; Prognosis; Pyridines; Radiosurgery; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate | 2019 |
Phosphorylation of HSF1 by PIM2 Induces PD-L1 Expression and Promotes Tumor Growth in Breast Cancer.
Topics: Aminopyridines; Animals; Autophagy; B7-H1 Antigen; Benzylidene Compounds; Breast Neoplasms; Carboplatin; F-Box-WD Repeat-Containing Protein 7; Female; Gene Expression Regulation, Neoplastic; Heat Shock Transcription Factors; Humans; Indazoles; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplasm Proteins; Phosphorylation; Protein Binding; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Stability; Proto-Oncogene Proteins; RNA Interference; RNA, Small Interfering; Substrate Specificity; Thiazolidinediones; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2019 |
Toxic epidermal necrolysis associated with ribociclib in a patient with metastatic breast cancer.
Topics: Aminopyridines; Breast Neoplasms; Female; Humans; Purines; Stevens-Johnson Syndrome | 2020 |
CDK 4/6 inhibitor successful rechallenge after limiting hepatic toxicity.
Topics: Alanine Transaminase; Aminopyridines; Aromatase Inhibitors; Aspartate Aminotransferases; Bone Neoplasms; Breast Neoplasms; Carcinoma, Lobular; Chemical and Drug Induced Liver Injury; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Substitution; Drug Therapy, Combination; Female; Humans; Letrozole; Middle Aged; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines | 2020 |
[Pharmacological Effects of CDK4 & 6 Selective Inhibitor Abemaciclib in Hormone Receptor-Positive Breast Cancer].
Topics: Aminopyridines; Animals; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Humans; Protein Kinase Inhibitors | 2019 |
Abemaciclib plus fulvestrant for breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase III as Topic; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Progression-Free Survival; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2019 |
CDK4/6 inhibitors prolong OS.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Fulvestrant; Humans; Receptor, ErbB-2 | 2019 |
Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Female; Humans; Letrozole; Liver; Middle Aged; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Zoledronic Acid | 2020 |
Ribociclib and Endocrine Therapy in Breast Cancer.
Topics: Aminopyridines; Breast Neoplasms; Humans; Purines | 2019 |
Ribociclib and Endocrine Therapy in Breast Cancer. Reply.
Topics: Aminopyridines; Breast Neoplasms; Humans; Purines | 2019 |
Association between ribociclib and changes in creatinine in patients with hormone receptor positive metastatic breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Creatinine; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; New South Wales; Purines; Receptor, ErbB-2; Retrospective Studies | 2019 |
Time for a shift in molecular down staging in luminal breast cancer.
Topics: Aminopyridines; Breast Neoplasms; Female; Humans; Letrozole; Postmenopause; Purines; Receptor, ErbB-2; Receptors, Progesterone | 2020 |
Glucose restriction reverses the Warburg effect and modulates PKM2 and mTOR expression in breast cancer cell lines.
Topics: Adenosine Triphosphate; Aminopyridines; Blotting, Western; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Colorimetry; Down-Regulation; Flow Cytometry; Glucose; Humans; Lactic Acid; MCF-7 Cells; Membrane Proteins; Piperidines; Thyroid Hormone-Binding Proteins; Thyroid Hormones; TOR Serine-Threonine Kinases | 2019 |
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.
Topics: Aminopyridines; Animals; Breast Neoplasms; Culture Media, Conditioned; Epithelial Cells; Female; Humans; I-kappa B Kinase; Inflammation; Macrophages; Mammary Glands, Human; Mice; Obesity; Protein Serine-Threonine Kinases; Serine | 2020 |
[Ribociclib in combination with endocrine therapy improves overall survival of pre-/perimenopausal breast cancer patients].
Topics: Aminopyridines; Breast Neoplasms; Humans; Perimenopause; Purines | 2020 |
Cdk4 and Cdk6 Couple the Cell-Cycle Machinery to Cell Growth via mTORC1.
Topics: Aminopyridines; Animals; Benzimidazoles; Breast Neoplasms; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Proliferation; Cyclin D; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Humans; Mechanistic Target of Rapamycin Complex 1; Mice; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyridines; Tuberous Sclerosis Complex 2 Protein | 2020 |
CDK4/6 inhibition in HER2-positive breast cancer.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans; Trastuzumab | 2020 |
Treatment options for patients with HR+/HER2- advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy.
Topics: Aminopyridines; Betacoronavirus; Breast Neoplasms; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral; Purines; SARS-CoV-2; Triage | 2020 |
Response to the article by Dietz et al. entitled "Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID‑19 pandemic. The COVID‑19 pandemic breast cancer consortium".
Topics: Aminopyridines; Betacoronavirus; Breast Neoplasms; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral; Purines; SARS-CoV-2; Triage | 2020 |
Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Fulvestrant; Humans; Receptor, ErbB-2 | 2020 |
Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Fulvestrant; Humans; Receptor, ErbB-2 | 2020 |
Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer-Reply.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Fulvestrant; Humans; Receptor, ErbB-2 | 2020 |
Ribociclib plus Fulvestrant in Advanced Breast Cancer.
Topics: Aminopyridines; Breast Neoplasms; Fulvestrant; Humans; Purines | 2020 |
Ribociclib plus Fulvestrant in Advanced Breast Cancer. Reply.
Topics: Aminopyridines; Breast Neoplasms; Fulvestrant; Humans; Purines | 2020 |
Henoch-schönlein Purpura (HSP) in a patient on Abemaciclib.
Topics: Aged; Aminopyridines; Benzimidazoles; Breast Neoplasms; Female; Humans; IgA Vasculitis | 2020 |
Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer.
Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Japan; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Purines; Treatment Outcome | 2020 |
Cyclin-Dependent Kinase 4/6 Inhibitors Combined With Radiotherapy for Patients With Metastatic Breast Cancer.
Topics: Adult; Aged; Aminopyridines; Benzimidazoles; Breast Neoplasms; Cancer Pain; Chemoradiotherapy; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organs at Risk; Pain Measurement; Palliative Care; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Radiotherapy Dosage; Treatment Outcome | 2020 |
Ribociclib therapy in peritoneal carcinomatosis secondary to HER2-negative metastatic breast cancer: A clinical case with a positive outcome.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Peritoneal Neoplasms; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2020 |
A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Goserelin; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Receptor, ErbB-2; Tamoxifen; Thiazoles | 2021 |
Autophagic Vacuole Secretion Triggered by Chidamide Participates in TRAIL Apoptosis Effect in Breast Cancer Cells.
Topics: Aminopyridines; Apoptosis; Autophagosomes; Benzamides; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Histone Deacetylase Inhibitors; Humans; TNF-Related Apoptosis-Inducing Ligand; Vacuoles | 2021 |
A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients.
Topics: Aminopyridines; Breast Neoplasms; Combined Modality Therapy; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Ileitis; Molecular Targeted Therapy; Neoplasm Metastasis; Neutropenia; Outcome Assessment, Health Care; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Radiotherapy; Retrospective Studies | 2020 |
Her2 promotes early dissemination of breast cancer by suppressing the p38-MK2-Hsp27 pathway that is targetable by Wip1 inhibition.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Dipeptides; Female; Heat-Shock Proteins; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase 14; Molecular Chaperones; Neoplasm Metastasis; Phosphorylation; Protein Phosphatase 2C; Protein Serine-Threonine Kinases; Pyridines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2020 |
Serum concentration of the CKD4/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a preliminary report.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Creatinine; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neutrophils; Patient Acuity; Platelet Count | 2021 |
Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Retinoblastoma Binding Proteins; Ubiquitin-Protein Ligases | 2021 |
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Purines; Receptors, Estrogen; Thiazoles | 2021 |
CDK4/6 Inhibition in Early-Stage Breast Cancer: The New Standard?
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Humans; Reference Standards | 2020 |
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Receptor, ErbB-2 | 2021 |
Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Drug Costs; Female; Follow-Up Studies; Goserelin; Humans; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Premenopause; Progression-Free Survival; Purines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Singapore; Survival Rate; Treatment Outcome | 2021 |
Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Substitution; Female; Humans; Middle Aged; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Transaminases; Treatment Outcome | 2020 |
Abemaciclib-induced reversible grade 4 nephrotoxicity.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Female; Humans | 2020 |
Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?
Topics: Aminopyridines; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Goserelin; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Tamoxifen; Thiazoles | 2021 |
Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Piperazines; Purines; Pyridines; Retrospective Studies | 2021 |
Local Targeting of Lung-Tumor-Associated Macrophages with Pulmonary Delivery of a CSF-1R Inhibitor for the Treatment of Breast Cancer Lung Metastases.
Topics: Administration, Inhalation; Administration, Intravenous; Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; Paclitaxel; Phosphorylation; Pyrroles; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Tumor Microenvironment; Tumor-Associated Macrophages | 2020 |
Molecular pathogenesis of breast cancer: impact of miR-99a-5p and miR-99a-3p regulation on oncogenic genes.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Estrogens; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Genes, Tumor Suppressor; Humans; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; MicroRNAs; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nuclear Proteins; Oncogenes; Piperazines; Progesterone; Prognosis; Progression-Free Survival; Pyridines; RNA Interference; RNA, Neoplasm; RNA, Small Interfering; Treatment Outcome | 2021 |
CDK4/6 inhibitors for HR
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Humans | 2021 |
Coronary Plaque Erosion after Abemaciclib Treatment Onset: An Unknown Side Effect?
Topics: Aged; Aminopyridines; Antineoplastic Agents; Artifacts; Benzimidazoles; Breast Neoplasms; Coronary Vessels; Enoxaparin; Female; Humans; Lipids; Myocardial Infarction; Protein Kinase Inhibitors; Thromboembolism; Ticagrelor; Treatment Outcome | 2021 |
Hepatotoxicity associated with ribociclib among breast cancer patients.
Topics: Aminopyridines; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Female; Humans; Purines | 2021 |
Complete response of leptomeningeal carcinomatosis secondary to breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Humans; Letrozole; Meningeal Carcinomatosis; Middle Aged; Radiotherapy, Adjuvant | 2020 |
CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Uncertainty | 2021 |
A quantitative systems pharmacological approach identified activation of JNK signaling pathway as a promising treatment strategy for refractory HER2 positive breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; MAP Kinase Signaling System; Network Pharmacology; Protein Interaction Maps; Protein Kinase Inhibitors; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2021 |
Prognosis Varies by Intrinsic Tumor Subtype in Patients Treated with Ribociclib.
Topics: Aminopyridines; Breast Neoplasms; Female; Humans; Neoplasms; Prognosis; Purines | 2021 |
Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Female; Humans; Japan; Lung Diseases, Interstitial; Middle Aged; Product Surveillance, Postmarketing; Tomography, X-Ray Computed | 2021 |
[Locally Advanced Breast Cancer Successfully Treated with Abemaciclib and Fulvestrant-A Case Report].
Topics: Aged; Aminopyridines; Axilla; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Lymph Node Excision; Lymph Nodes; Mastectomy; Neoplasm Recurrence, Local | 2020 |
Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Humans; Piperazines; Purines; Pyridines; Receptor, ErbB-2 | 2021 |
Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2- metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Purines; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies | 2021 |
Ribociclib induced acute kidney injury: A case report.
Topics: Acute Kidney Injury; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Purines; Receptors, Estrogen | 2021 |
Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Diarrhea; Female; Humans; Neutropenia; Receptor, ErbB-2 | 2021 |
Acute generalised exanthematous pustulosis after initiation of palbociclib therapy for metastatic breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Exanthema; Female; Humans; Piperazines; Purines; Pyridines | 2021 |
Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Humans; Receptor, ErbB-2; Receptors, Estrogen | 2021 |
[A Case of Palbociclib plus Fulvestrant‒Resistant Metastatic Breast Cancer That Responded to Abemaciclib plus Fulvestrant].
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Piperazines; Pyridines | 2021 |
Fatal acute hepatic failure secondary to thrombotic portal venopathy after commencing abemaciclib and fulvestrant treatment for advanced breast carcinoma: a unique autopsy finding.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Liver Failure, Acute; Receptor, ErbB-2 | 2021 |
Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Canada; Cost-Benefit Analysis; Delivery of Health Care; Female; Humans; Perimenopause; Purines; Quality-Adjusted Life Years | 2021 |
[A Case of Hormone Receptor‒Positive HER2‒Negative Advanced/Recurrent Breast Cancer with 1.5 Years Withdrawal Period of Palbociclib Showed a Good Response Treated by Abemaciclib and Fulvestrant].
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyridines | 2021 |
High MMP-11 expression associated with low CD8+ T cells decreases the survival rate in patients with breast cancer.
Topics: Aminopyridines; Breast Neoplasms; CD8-Positive T-Lymphocytes; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Lymphocytes, Tumor-Infiltrating; Matrix Metalloproteinase 11; MCF-7 Cells; Middle Aged; Pyrazoles; Receptor, ErbB-2; Sulfonamides; Survival Analysis; Survival Rate; Tumor Microenvironment | 2021 |
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Cost-Benefit Analysis; Delivery of Health Care; Female; Fulvestrant; Humans; Postmenopause; Purines; Receptor, ErbB-2 | 2021 |
A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Female; Humans; Massive Hepatic Necrosis; Middle Aged; Purines | 2022 |
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gain of Function Mutation; Humans; Mice, Nude; Molecular Docking Simulation; Molecular Dynamics Simulation; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Multimerization; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; Trastuzumab; Xenograft Model Antitumor Assays | 2021 |
Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice.
Topics: Aged; Aminopyridines; Breast Neoplasms; Databases, Factual; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Piperazines; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate | 2021 |
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Benzimidazoles; Breast Neoplasms; Drug Combinations; Female; Fulvestrant; Humans; Neoplasm Staging; Progression-Free Survival; Receptor, ErbB-2; Treatment Outcome | 2021 |
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer.
Topics: Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Purines; Receptors, Estrogen; Thiazoles; Thiophenes | 2021 |
FDA approves Novartis's CDK4/6 inhibitor.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Approval; Drug Industry; Female; Humans; Purines; United States; United States Food and Drug Administration | 2017 |
Ribociclib: First Global Approval.
Topics: Administration, Oral; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Approval; Enzyme Inhibitors; Female; Humans; Purines; United States; United States Food and Drug Administration | 2017 |
Astex shapes CDK4/6 inhibitor for approval.
Topics: Aminopyridines; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Approval; Drug Industry; Female; Humans; Purines; United States; United States Food and Drug Administration | 2017 |
Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Breast Cancer: More Breakthroughs and an Embarrassment of Riches.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Embarrassment; Female; Fulvestrant; Humans | 2017 |
Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate.
Topics: Aminopyridines; Anilides; Animals; Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase 9; Drug Screening Assays, Antitumor; Female; Humans; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Protein Kinase Inhibitors; Purines; Pyridines | 2017 |
Informed Consent and Decision Making Among Participants in Novel-Design Phase I Oncology Trials.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Decision Making; Female; Humans; Informed Consent; Morpholines; Motivation; Neoplasm Metastasis; Protein Kinase Inhibitors; Qualitative Research; Research Subjects | 2017 |
Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib.
Topics: Aminopyridines; Breast Neoplasms; Female; Humans; Molecular Targeted Therapy; Purines; Translational Research, Biomedical | 2017 |
Ribociclib (Kisqali) for advanced or metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Neoplasm Metastasis; Protein Kinase Inhibitors; Purines; Signal Transduction; Treatment Outcome | 2017 |
Abemaciclib (Verzenio)--a third CDK 4/6 inhibitor for breast cancer.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Protein Kinase Inhibitors; Signal Transduction; Treatment Outcome | 2017 |
NICE recommends routine NHS funding for new breast cancer drugs.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Drug Costs; Female; Humans; Piperazines; Purines; Pyridines; State Medicine; United Kingdom | 2017 |
Efficacy of buparlisib in treating breast cancer.
Topics: Aminopyridines; Breast Neoplasms; Clinical Trials as Topic; Female; Half-Life; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; TOR Serine-Threonine Kinases | 2017 |
A2B adenosine receptor agonist induces cell cycle arrest and apoptosis in breast cancer stem cells via ERK1/2 phosphorylation.
Topics: Adenosine A2 Receptor Agonists; Aminopyridines; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplastic Stem Cells; Phosphorylation; Receptor, Adenosine A2B | 2018 |
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Genotype; Humans; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Retinoblastoma Binding Proteins; Ubiquitin-Protein Ligases | 2018 |
Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer.
Topics: Aminopyridines; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogen Receptor alpha; Female; Half-Life; Humans; Neoplasm Staging; Purines; Receptor, ErbB-2; T-Lymphocytes; Treatment Outcome | 2018 |
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Female; Humans; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Protein Kinase Inhibitors; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Research Design; Treatment Outcome | 2018 |
Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Humans; Postmenopause; Purines | 2018 |
[CDK4/6 inhibitors: biomarkers, mechanisms of resistance and interest of the study of the circulating tumor DNA].
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Mutation; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Retinoblastoma Binding Proteins; Ubiquitin-Protein Ligases | 2018 |
Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Letrozole; Models, Biological; Models, Economic; Nitriles; Piperazines; Postmenopause; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Treatment Outcome; Triazoles; United States | 2018 |
Ribociclib in premenopausal women with advanced breast cancer.
Topics: Aminopyridines; Breast; Breast Neoplasms; Female; Humans; Purines | 2018 |
Expanding ribociclib use.
Topics: Aminopyridines; Breast; Breast Neoplasms; Female; Humans; Purines | 2018 |
Radiation-induced morphea-a rare but severe late effect of adjuvant breast irradiation : Case report and review of the literature.
Topics: Aged; Aminopyridines; Anastrozole; Benzimidazoles; Biopsy; Breast; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Mastectomy, Segmental; Neoadjuvant Therapy; Neoplasm Staging; Radiation Injuries; Radiotherapy, Adjuvant; Scleroderma, Localized | 2018 |
Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Budgets; Female; Humans; Letrozole; Postmenopause; Purines; Receptor, ErbB-2; Receptors, Estrogen; United States | 2018 |
Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Italy; Middle Aged; Palliative Care; Purines; Radiotherapy, Adjuvant | 2018 |
Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Carcinoma, Lobular; Colonic Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2018 |
Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; China; Cost-Benefit Analysis; Drug Costs; Female; Humans; Letrozole; Progression-Free Survival; Purines; Quality-Adjusted Life Years; Receptors, Estrogen; Receptors, Progesterone | 2019 |
PI3K: A master regulator of brain metastasis-promoting macrophages/microglia.
Topics: Adult; Aged; Aminopyridines; Animals; Brain Neoplasms; Breast Neoplasms; Calcium-Binding Proteins; Disease Models, Animal; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Glial Fibrillary Acidic Protein; Humans; Macrophages; Mice; Mice, Inbred BALB C; Microfilament Proteins; Microglia; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinases; Signal Transduction; TOR Serine-Threonine Kinases | 2018 |
Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate.
Topics: Aminopyridines; Antineoplastic Agents, Immunological; Benzimidazoles; Biological Transport; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Kidney Tubules; Metabolic Clearance Rate; Metformin; Organic Cation Transport Proteins; Organic Cation Transporter 2 | 2019 |
Why upfront use of CDK inhibitors for the treatment of advanced breast cancer may be wasteful, and how we can increase their value.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Benzimidazoles; Breast Neoplasms; Cost-Benefit Analysis; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Costs; Female; Humans; Neutropenia; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptors, Estrogen; Receptors, Progesterone | 2019 |
PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study.
Topics: Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Female; Humans; Metaplasia; Morpholines; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Randomized Controlled Trials as Topic; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Pharmacological inhibition of the IKKε/TBK-1 axis potentiates the anti-tumour and anti-metastatic effects of Docetaxel in mouse models of breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Synergism; Female; Humans; I-kappa B Kinase; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Serine-Threonine Kinases; RAW 264.7 Cells | 2019 |
Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Letrozole; Markov Chains; Models, Economic; Piperazines; Purines; Pyridines; Quality of Life; Receptor, ErbB-2; Survival Analysis; Treatment Outcome | 2019 |
Micellar Formulation of Talazoparib and Buparlisib for Enhanced DNA Damage in Breast Cancer Chemoradiotherapy.
Topics: Aminopyridines; Animals; Breast Neoplasms; Cell Line, Tumor; Chemoradiotherapy; DNA Damage; Female; Humans; Mice; Mice, Inbred BALB C; Micelles; Morpholines; Phthalazines; Xenograft Model Antitumor Assays | 2019 |
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Circulating Tumor DNA; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fulvestrant; High-Throughput Nucleotide Sequencing; Humans; MCF-7 Cells; Mice; Mutation; Naphthalenes; Piperazines; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Quinolines; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Estrogen; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
Patients' preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Diarrhea; Female; Fulvestrant; Humans; Japan; Middle Aged; Patient Preference; Postmenopause; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Socioeconomic Factors; Surveys and Questionnaires | 2019 |
Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: Preliminary assessment of toxicity.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Chemoradiotherapy; ErbB Receptors; Female; Humans; Middle Aged; Neutropenia; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Radiation Dosage; Treatment Outcome | 2019 |
Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicity.
Topics: Aminopyridines; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Benzimidazoles; Breast Neoplasms; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Doxorubicin; Drug Screening Assays, Antitumor; Female; Humans; Killer Cells, Natural; Molecular Targeted Therapy; Neoplasm Recurrence, Local | 2019 |
Ribociclib Causing Transient Glanzmann Thrombasthenia-like Picture: A Report of 4 Cases.
Topics: Aminopyridines; Blood Platelet Disorders; Breast Neoplasms; Female; Humans; Middle Aged; Postmenopause; Protein Kinase Inhibitors; Purines | 2019 |
Achieving Improved Survival Outcomes in Advanced Breast Cancer.
Topics: Aminopyridines; Breast; Breast Neoplasms; Humans; Purines | 2019 |
Quantification of Economic Impact of Drug Wastage in Oral Oncology Medications: Comparison of 3 Methods Using Palbociclib and Ribociclib in Advanced or Metastatic Breast Cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Drug Costs; Drug Utilization; Evaluation Studies as Topic; Female; Health Care Costs; Humans; Middle Aged; Models, Economic; Piperazines; Purines; Pyridines; Randomized Controlled Trials as Topic; Retrospective Studies | 2019 |
Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents.
Topics: Aminopyridines; Aurora Kinase B; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromosome Aberrations; Drug Resistance, Neoplasm; Female; Histones; Humans; Phosphorylation; Polyploidy; Protein Kinase Inhibitors; Pyridones; Receptor Protein-Tyrosine Kinases; Spindle Apparatus | 2013 |
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; MCF-7 Cells; Mice; Mice, Nude; Molecular Targeted Therapy; Morpholines; Open Reading Frames; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Ribosomal Protein S6 Kinases, 90-kDa; Signal Transduction; Transcriptome; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Everolimus; Female; Humans; Imidazoles; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2013 |
The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome.
Topics: Alleles; Aminopyridines; Animals; Breast Neoplasms; Class Ia Phosphatidylinositol 3-Kinase; Disease Models, Animal; Female; Gene Dosage; Genotype; Hamartoma Syndrome, Multiple; Mice; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Skin Neoplasms | 2013 |
Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics.
Topics: Aging; Aminopyridines; Breast; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Morpholines; Polyploidy; Protein Kinase Inhibitors; Pyridones; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
Topics: Aminopyridines; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mice; Mice, Nude; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2014 |
Synthesis, characterization, and evaluation of cis-diphenyl pyridineamine platinum(II) complexes as potential anti-breast cancer agents.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Cell Survival; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; MCF-7 Cells; Models, Molecular; Molecular Structure; Organoplatinum Compounds; Structure-Activity Relationship; Tumor Cells, Cultured | 2014 |
Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition.
Topics: Aminopyridines; Apoptosis; Breast Neoplasms; DNA-Binding Proteins; Female; Gene Knockdown Techniques; Heterocyclic Compounds, 3-Ring; Humans; MCF-7 Cells; Morpholines; Nuclear Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Small Interfering; Signal Transduction; Transcription Factors; Transfection | 2014 |
Cell cycle inhibitors make progress.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Cycle; Clinical Trials, Phase I as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Purines; Pyridines; Randomized Controlled Trials as Topic; ras Proteins; Receptors, Estrogen | 2014 |
MEL-18 loss mediates estrogen receptor-α downregulation and hormone independence.
Topics: Aminopyridines; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Endopeptidases; Estrogen Receptor alpha; Estrogens; Female; Humans; Kaplan-Meier Estimate; Mice; Morpholines; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Polycomb Repressive Complex 1; Progesterone; Proportional Hazards Models; Proteasome Endopeptidase Complex; Protein Processing, Post-Translational; Receptor, ErbB-2; Receptors, Progesterone; RNA, Messenger; RNA, Neoplasm; Sp1 Transcription Factor; Sumoylation; Tamoxifen; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53 | 2015 |
β-Adrenergic receptors suppress Rap1B prenylation and promote the metastatic phenotype in breast cancer cells.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Antagonists; Aminopyridines; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Membrane; Cell Movement; Female; GTP-Binding Protein alpha Subunits, Gs; Humans; Isoproterenol; Neoplasm Metastasis; Phenotype; Phosphorylation; Propranolol; Protein Prenylation; Protein Transport; rap GTP-Binding Proteins; Receptors, Adrenergic, beta; Signal Transduction | 2015 |
Inhibition of cyclin-dependent kinases 4 and 6 in breast cancer.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase II as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptors, Estrogen; Research; Treatment Outcome | 2015 |
Molecular diagnostics for precision medicine in breast cancer treatment: what does the future hold?
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Pathology, Molecular; Piperazines; Precision Medicine; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; TOR Serine-Threonine Kinases; Trastuzumab | 2016 |
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphoinositide-3 Kinase Inhibitors; Postmenopause; PTEN Phosphohydrolase; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2016 |
Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells.
Topics: Aminopyridines; Animals; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Morpholines; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Signal Transduction | 2015 |
PI3K Inhibitor Improves PFS in BELLE-2 Trial.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Congresses as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Treatment Outcome | 2016 |
Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.
Topics: Aminopyridines; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Proliferation; Dipeptides; DNA Damage; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Piperazines; Protein Phosphatase 2C; Proto-Oncogene Proteins c-mdm2; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2016 |
New p32/gC1qR Ligands for Targeted Tumor Drug Delivery.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Drug Delivery Systems; Ethylenediamines; Female; Humans; Ligands; Mice; Mitochondrial Proteins; Nanoparticles; Peptides, Cyclic | 2016 |
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease Models, Animal; Drug Monitoring; Female; Humans; Lung Neoplasms; Male; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases.
Topics: Adaptor Proteins, Signal Transducing; Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Breast Neoplasms; Carrier Proteins; Caspase 3; Cell Cycle Proteins; DNA Repair; Drug Resistance, Neoplasm; Drug Therapy, Combination; Eukaryotic Initiation Factors; Everolimus; Female; Gene Expression Profiling; Genomic Instability; Humans; Immunohistochemistry; Ki-67 Antigen; Magnetic Resonance Imaging; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, SCID; Molecular Targeted Therapy; Morpholines; Multiprotein Complexes; Neoplasm Transplantation; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Phosphorylation; Receptor, ErbB-2; Remission Induction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Single-Agent Abemaciclib Active in Breast Cancer.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase II as Topic; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 2016 |
CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Male; Neoplasms; Treatment Outcome | 2016 |
Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
Topics: Aminopyridines; Animals; Antibodies; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Lapatinib; Mice; Morpholines; ortho-Aminobenzoates; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; PTEN Phosphohydrolase; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Thiazoles; Xenograft Model Antitumor Assays | 2016 |
Ribociclib in HR-positive, HER2-negative breast cancer.
Topics: Aminopyridines; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Protein Kinase Inhibitors; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2016 |
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Gene Amplification; Humans; MCF-7 Cells; Protein Kinase Inhibitors; Receptors, Estrogen; Signal Transduction | 2017 |
Ribociclib Lengthens Breast Cancer Survival.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Purines; Treatment Outcome; Triazoles | 2016 |
Abemaciclib Shows Promise for Early Breast Cancer.
Topics: Aminopyridines; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase II as Topic; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Nitriles; Receptor, ErbB-2; Survival Analysis; Treatment Outcome; Triazoles | 2017 |
Benefit Mixed with Caution for Buparlisib.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Morpholines; Postmenopause; Protein Kinase Inhibitors; Survival Analysis; Treatment Outcome | 2017 |
Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
Topics: 14-3-3 Proteins; Active Transport, Cell Nucleus; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Cytoplasm; Dose-Response Relationship, Drug; Female; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Hydroxychloroquine; Morpholines; Mutation; Protein Kinase Inhibitors; RNA Interference; Signal Transduction; Time Factors; Transfection; Uterine Cervical Neoplasms | 2017 |
[Cell cycle inhibitors in endocrine receptor positive breast cancer].
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Cycle; Cell Cycle Checkpoints; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Neoplasms, Hormone-Dependent; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines | 2017 |
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
Topics: Aminopyridines; Animals; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Indazoles; MCF-7 Cells; Mice; Phosphatidylinositol 3-Kinases; Piperazines; Protein Serine-Threonine Kinases; Purines; Pyridines; Pyrimidines; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Receptors, Estrogen; Xenograft Model Antitumor Assays | 2017 |
Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.
Topics: Administration, Oral; Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Crk-Associated Substrate Protein; Female; Focal Adhesion Protein-Tyrosine Kinases; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Phosphorylation; Tyrosine; Xenograft Model Antitumor Assays | 2010 |
New evidence in pulmonary and preventive medicine.
Topics: Adrenergic beta-Agonists; Albuterol; Aminopyridines; Benzamides; Breast Neoplasms; Bronchodilator Agents; Cyclopropanes; Disease Progression; Early Detection of Cancer; Evidence-Based Medicine; Female; Humans; Papillomavirus Vaccines; Preventive Medicine; Primary Prevention; Pulmonary Disease, Chronic Obstructive; Salmeterol Xinafoate; Scopolamine Derivatives; Secondary Prevention; Tiotropium Bromide; Uterine Cervical Neoplasms | 2010 |
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Estradiol; Estrogens; Everolimus; Female; Fulvestrant; Humans; Imidazoles; Morpholines; Mutation; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Quinolines; Receptors, Estrogen; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2011 |
Discovery of new aminopyrimidine-based phosphoinositide 3-kinase beta (PI3Kβ) inhibitors with selectivity over PI3Kα.
Topics: Aminopyridines; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Drug Discovery; Enzyme Activation; Enzyme Inhibitors; Female; Humans; Hydrogen Bonding; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Isoforms; Pyrimidinones; Substrate Specificity | 2011 |
Adhesion and migration of extracellular matrix-stimulated breast cancer.
Topics: Acetates; Aminopyridines; Antibodies, Monoclonal; Benzodiazepinones; Breast Neoplasms; Cell Adhesion; Cell Movement; Extracellular Matrix; Female; Fibronectins; Humans; Integrin alphaVbeta3; Integrin beta Chains; Integrins; Peptide Fragments; Receptors, Vitronectin; Tumor Cells, Cultured; Vitronectin | 2003 |